[go: up one dir, main page]

CN104961672B - A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea - Google Patents

A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea Download PDF

Info

Publication number
CN104961672B
CN104961672B CN201510259570.7A CN201510259570A CN104961672B CN 104961672 B CN104961672 B CN 104961672B CN 201510259570 A CN201510259570 A CN 201510259570A CN 104961672 B CN104961672 B CN 104961672B
Authority
CN
China
Prior art keywords
isobutoxybenzyl
fluorobenzyl
solvent
urea
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510259570.7A
Other languages
Chinese (zh)
Other versions
CN104961672A (en
Inventor
王绍杰
王瀚培
赵龙山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Shenzhou Kang Sheng Pharmaceutical Technology Co Ltd
Shenyang Pharmaceutical University
Original Assignee
Hainan Shenzhou Kang Sheng Pharmaceutical Technology Co Ltd
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hainan Shenzhou Kang Sheng Pharmaceutical Technology Co Ltd, Shenyang Pharmaceutical University filed Critical Hainan Shenzhou Kang Sheng Pharmaceutical Technology Co Ltd
Priority to CN201510259570.7A priority Critical patent/CN104961672B/en
Publication of CN104961672A publication Critical patent/CN104961672A/en
Application granted granted Critical
Publication of CN104961672B publication Critical patent/CN104961672B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

本发明属于医药技术领域,涉及一种N‑(4‑氟苄基)‑N‑(1‑甲基哌啶‑4‑基)‑N’‑(4‑异丁氧基苄基)脲的酒石酸盐的合成方法,本发明是以4‑羟基苄胺为原料,经过氨基保护、烃化反应得到N‑保护基‑4‑异丁氧基苄胺,然后经过脱保护反应制得关键中间体4‑异丁氧基苄胺,再与氯甲酸苯酯反应制得N‑(4‑异丁氧基苄基)氨基甲酸苯酯,最后通过与另一中间体N‑(4‑氟苄基)‑1‑甲基‑4‑哌啶胺的氨解反应制得N‑(4‑氟苄基)‑N‑(1‑甲基哌啶‑4‑基)‑N’‑(4‑异丁氧基苄基)脲,与酒石酸成盐,得到N‑(4‑氟苄基)‑N‑(1‑甲基哌啶‑4‑基)‑N’‑(4‑异丁氧基苄基)脲的酒石酸盐。本发明原料易得、操作简单温和、生产周期短、收率高、安全性好、成本低、适合工业化生产。The invention belongs to the technical field of medicine, and relates to a kind of N- (4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) -N ' -(4-isobutoxybenzyl) urea The synthetic method of tartrate, the present invention is to take 4-hydroxybenzylamine as raw material, obtain N -protecting group-4-isobutoxybenzylamine through amino protection, alkylation reaction, then make key intermediate through deprotection reaction 4-isobutoxybenzylamine, then reacts with phenyl chloroformate to obtain N- (4-isobutoxybenzyl) phenyl carbamate, and finally passes through with another intermediate N- (4-fluorobenzyl )-1-methyl-4-piperidinamine by ammonolysis to N- (4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) -N ' -(4-iso Butoxybenzyl) urea, with tartaric acid salt formation, to obtain N- (4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) -N ' -(4-isobutoxybenzyl base) tartrate of urea. The invention has easy-to-obtain raw materials, simple and mild operation, short production period, high yield, good safety and low cost, and is suitable for industrialized production.

Description

一种N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基 苄基)脲的酒石酸盐的合成方法A kind of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxy The synthetic method of the tartrate of benzyl) urea

技术领域technical field

本发明属于医药技术领域,涉及一种N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法,还涉及其中间体N-保护基-4-羟基苄胺、N-保护基-4-异丁氧基苄胺、4-异丁氧基苄胺和N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法。The invention belongs to the technical field of medicine, and relates to a kind of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea The synthetic method of tartrate also relates to its intermediate N-protecting group-4-hydroxybenzylamine, N-protecting group-4-isobutoxybenzylamine, 4-isobutoxybenzylamine and N-(4- The synthetic method of isobutoxybenzyl) phenyl carbamate.

背景技术Background technique

帕金森氏综合征(Parkinsonism)是一种慢性的中枢神经系统退化性失调,以某些运动障碍(静止性震颤、肌强直、运动迟缓和姿势反射丧失)为临床特征的疾病。它会损害患者的动作技能、语言能力以及其他功能。它的病因目前仍不明,推测和大脑底部基底核以及黑质脑细胞快速退化,无法制造足够的神经引导物质多巴胺(DA)有关(Friedman,1991,Goetz et al,2001)。Parkinson's syndrome (Parkinsonism) is a chronic degenerative disorder of the central nervous system, clinically characterized by certain movement disorders (rest tremor, muscle rigidity, bradykinesia and loss of postural reflexes). It can impair a patient's motor skills, speech, and other functions. Its etiology is still unknown, and it is speculated that it is related to the rapid degeneration of brain cells in the basal ganglia and substantia nigra of the brain, which cannot produce enough neuroguiding substance dopamine (DA) (Friedman, 1991, Goetz et al, 2001).

目前全世界帕金森氏病患者人数达到七百万到一千万,中国约260万,居世界第一。40%以上的帕金森氏病患者曾有过精神性疾病。精神疾病给帕金森氏病患者的治疗和护理带来更大挑战。在帕金森病患者中,精神症状是导致患者住院的首要原因,它也使得患者的死亡风险显著增高(Weintraub and Stern,2005;Factor et al,2003)。At present, the number of patients with Parkinson's disease in the world has reached 7 million to 10 million, and China has about 2.6 million, ranking first in the world. More than 40% of people with Parkinson's disease have had a mental illness. Mental illness presents greater challenges in the treatment and care of people with Parkinson's disease. In patients with Parkinson's disease, psychiatric symptoms are the leading cause of hospitalization and significantly increase the risk of death (Weintraub and Stern, 2005; Factor et al, 2003).

精神性疾病,例如精神分裂症以及相关的特发性精神病,其发病原因及现行抗精神病药起效的分子基础,医学界未完全研究清楚,从而使精神性病症治疗药物的合理性设计和制备面临极大困难。研究表明,精神性病症的阳性症状与多巴胺的活动亢进有关,阴性症状于中枢5-羟色胺(5-HT)功能的提高及DA功能尤其是前额叶DA功能的下降有关(Romrell et al,2003)。Mental diseases, such as schizophrenia and related idiopathic psychosis, the causes of their pathogenesis and the molecular basis of the onset of current antipsychotic drugs have not been fully studied in the medical field, so that the rational design and preparation of drugs for the treatment of psychiatric disorders face great difficulties. Studies have shown that the positive symptoms of mental disorders are related to the hyperactivity of dopamine, and the negative symptoms are related to the increase of central 5-hydroxytryptamine (5-HT) function and the decline of DA function, especially the prefrontal DA function (Romrell et al, 2003) .

由于精神性疾病发病机理一般认为其与患者脑内多巴胺过多相关,普遍抗精神病症药物的作用机制是多巴胺D2受体的拮抗作用(Chou et al,2007;Romrell et al,2003)。不幸的是,多巴胺D2受体拮抗剂除了引起椎体外周的副作用,还会让有精神疾病的帕金森氏病患加重病情(Molho and Factor,1999;Weintraub and Stern,2005)。Since the pathogenesis of psychiatric diseases is generally believed to be related to excessive dopamine in the brain of patients, the general mechanism of action of antipsychotic drugs is the antagonism of dopamine D2 receptors (Chou et al, 2007; Romrell et al, 2003). Unfortunately, dopamine D2 receptor antagonists, in addition to causing peripheral side effects, can also exacerbate Parkinson's disease in psychiatric patients (Molho and Factor, 1999; Weintraub and Stern, 2005).

匹莫范色林(Pimavanserin)是阿卡迪亚(Acadia)制药公司自主研发的专利药,用于治疗帕金森氏病精神症状,这是一种新的、可有效抑制5-HT2A单胺受体活性、而非多巴胺受体抑制的药物(Herbert Y Meltzer,Roger Mills et al,2010)。匹莫范色林于2014年9月3日获美国食品药品监督管理局授予突破性疗法认证。阿卡迪亚制药公司已于2014年向FDA递交匹莫范色林的新药申请。Pimavanserin (Pimavanserin) is a patent drug independently developed by Acadia (Acadia) pharmaceutical company, which is used to treat the mental symptoms of Parkinson's disease. Drugs that inhibit body activity rather than dopamine receptors (Herbert Y Meltzer, Roger Mills et al, 2010). Pimavanserin was granted Breakthrough Therapy Certification by the U.S. Food and Drug Administration on September 3, 2014. Arcadia Pharmaceuticals submitted a new drug application for pimavanserin to the FDA in 2014.

鉴于目前市场上治疗帕金森精神症状的药物十分有限,且都具有较强的毒副作用,所以 研制出一种低毒,疗效好的帕金森氏病精神类药物迫在眉睫。In view of the very limited drugs for the treatment of Parkinson's psychiatric symptoms on the market, and all have strong toxic and side effects, it is imminent to develop a kind of low toxicity and good Parkinson's disease psychotropic drugs.

根据US20060111399所提供的方法:以4-羟基苯甲醛为原料,先进行烃化反应制得4-异丁氧基苯甲醛,经脱水反应制得4-异丁氧基苯甲醛肟,然后经过氢气还原得到重要中间体4-异丁氧基苄胺,与三光气反应制得中间体4-异丁氧基苄基异氰酸酯,最后再与N-(4-氟苄基)-1-甲基-4-哌啶胺进行氨解反应制得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲,与酒石酸成盐,得到N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐,总收率:15.9%。该合成路线表示如下:According to the method provided by US20060111399: use 4-hydroxybenzaldehyde as raw material, first carry out alkylation reaction to obtain 4-isobutoxybenzaldehyde, and obtain 4-isobutoxybenzaldehyde oxime through dehydration reaction, and then pass through hydrogen Reduction to obtain the important intermediate 4-isobutoxybenzylamine, react with triphosgene to obtain the intermediate 4-isobutoxybenzyl isocyanate, and finally react with N-(4-fluorobenzyl)-1-methyl- Preparation of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea by ammonolysis of 4-piperidinamine , with tartaric acid to give the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea, Overall yield: 15.9%. The synthetic route is represented as follows:

该路线的缺点在于:整条路线周期长,收率不高,且使用光气制备异氰酸酯,光气通入反应釜会剧烈放热,不易操作,且有剧毒,工业上一旦发生泄漏,会产生严重的安全隐患和环境污染等问题。The disadvantages of this route are: the whole route has a long cycle, the yield is not high, and phosgene is used to prepare isocyanate. When phosgene is passed into the reactor, it will exotherm violently, is not easy to operate, and is highly toxic. Once a leak occurs in industry, it will Serious potential safety hazards and environmental pollution are caused.

发明内容Contents of the invention

本发明要解决的技术问题是针对现有工艺生产周期长、收率低、后处理繁杂、安全性差和环境污染等问题,提出一种新的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法,该方法制备周期短,收率高,且后处理简单,安全性高。The technical problem to be solved in the present invention is to propose a new N-(4-fluorobenzyl)-N-( A synthetic method for the tartrate of 1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea, the method has short preparation period, high yield, simple post-treatment and high safety high.

本发明采用如下技术方案:The present invention adopts following technical scheme:

以4-羟基苄胺为原料,经过氨基保护、烃化反应得到N-保护基-4-异丁氧基苄胺,然后经过脱保护反应制得关键中间体4-异丁氧基苄胺,再与氯甲酸苯酯反应制得N-(4-异丁氧基 苄基)氨基甲酸苯酯,最后通过与另一中间体N-(4-氟苄基)-1-甲基-4-哌啶胺的氨解反应制得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲,与酒石酸成盐,得到N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐。Using 4-hydroxybenzylamine as raw material, N-protecting group-4-isobutoxybenzylamine is obtained through amino protection and alkylation reaction, and then the key intermediate 4-isobutoxybenzylamine is obtained through deprotection reaction. Reaction with phenyl chloroformate to obtain N-(4-isobutoxybenzyl) phenyl carbamate, and finally by reacting with another intermediate N-(4-fluorobenzyl)-1-methyl-4- The aminolysis reaction of piperidinamine makes N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea, and Tartaric acid is salified to give the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea.

整个工艺包括如下步骤:The whole process includes the following steps:

(1)制备式II所述的N-保护基-4-羟基苄胺:(1) N-protecting group-4-hydroxybenzylamine described in the preparation formula II:

将4-羟基苄胺(I)、保护试剂、缚酸剂按照摩尔比1:(1.1-2.5):(1.2-3),优选比例为1:(1.2-1.5):(1.5-2),加入到溶剂中,-25~60℃,优选温度0~25℃反应0.5-24h,反应终止后,脱去溶剂,残留物用萃取试剂萃取,加水洗分层,弃去水层,脱去溶剂,制得N-保护基-4-羟基苄胺。With 4-hydroxybenzylamine (I), protection reagent, acid binding agent according to molar ratio 1:(1.1-2.5):(1.2-3), preferred ratio is 1:(1.2-1.5):(1.5-2), Add it into the solvent, react at -25~60℃, preferably at 0~25℃ for 0.5-24h, after the reaction is terminated, remove the solvent, extract the residue with an extraction reagent, add water to wash the layers, discard the water layer, and remove the solvent , to obtain N-protecting group-4-hydroxybenzylamine.

在上述制备方法中所用溶剂包括但不限于二氯甲烷、二氧六环、四氢呋喃、甲苯、乙腈、氯仿或各溶剂与水的混合溶剂,优选溶剂为二氯甲烷,4-羟基苄胺与溶剂的比例为1:2~10(m/v);The solvent used in the above preparation method includes but not limited to dichloromethane, dioxane, tetrahydrofuran, toluene, acetonitrile, chloroform or a mixed solvent of each solvent and water, the preferred solvent is dichloromethane, 4-hydroxybenzylamine and solvent The ratio is 1:2~10(m/v);

保护基团X为苄氧羰基、笏甲氧羰基、叔丁氧羰基、三甲基硅乙氧羰基、甲氧羰基、乙氧羰基、甲酰基、乙酰基、对甲苯磺酰基、三苯甲基、2,4-二甲氧基苄基、4-甲氧基苄基或苄基;Protecting group X is benzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, trimethylsilylethoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, formyl, acetyl, p-toluenesulfonyl, trityl , 2,4-dimethoxybenzyl, 4-methoxybenzyl or benzyl;

保护试剂为氯甲酸苄酯、芴甲氧甲酰氯、二碳酸二叔丁酯、2,2,2-三甲基硅乙氧甲酰氯、氯甲酸乙酯、氯甲酸甲酯、甲乙酐、乙酸酐、对甲苯磺酰氯、三苯基氯甲烷、2,4-二甲氧基苯甲醛、2,4-二甲氧基苄基氯、4-甲氧基苯甲醛、4-甲氧基苄基氯以及氯(溴)苄;Protecting reagents are benzyl chloroformate, fluorenylmethoxyformyl chloride, di-tert-butyl dicarbonate, 2,2,2-trimethylsilethoxyformyl chloride, ethyl chloroformate, methyl chloroformate, formic acetic anhydride, acetic acid Acid anhydride, p-toluenesulfonyl chloride, triphenylchloromethane, 2,4-dimethoxybenzaldehyde, 2,4-dimethoxybenzyl chloride, 4-methoxybenzaldehyde, 4-methoxybenzyl Chlorine and benzyl chloride (bromide);

所述萃取试剂为二氯甲烷、乙酸乙酯、甲苯、二氧六环,所选试剂为二氯甲烷;The extraction reagent is dichloromethane, ethyl acetate, toluene, dioxane, and the selected reagent is dichloromethane;

缚酸剂为碳酸氢钠、碳酸氢钾、三乙胺,优选缚酸剂为碳酸氢钠。The acid-binding agent is sodium bicarbonate, potassium bicarbonate, triethylamine, preferably the acid-binding agent is sodium bicarbonate.

(2)制备式III所示的N-保护基-4-异丁氧基苄胺:(2) N-protecting group-4-isobutoxybenzylamine shown in the preparation formula III:

将N-保护基-4-羟基苄胺、溴代异丁烷与缚酸剂按照摩尔比1:(1.2-3):(1.2-3),优选比例为1:(1.2-1.5):(1.5-2),加入溶剂中,50~82℃,优选温度55~82℃下反应12-36h,反应结束后,脱去溶剂,残留物用萃取试剂萃取,用碱水洗,弃掉水层,脱去溶剂,制得N-保护基-4-异丁氧基苄胺。The N-protecting group-4-hydroxybenzylamine, bromoisobutane and acid-binding agent are in a molar ratio of 1:(1.2-3):(1.2-3), preferably in a ratio of 1:(1.2-1.5):( 1.5-2), adding to the solvent, reacting for 12-36h at 50-82°C, preferably at a temperature of 55-82°C, after the reaction, remove the solvent, extract the residue with an extraction reagent, wash with alkaline water, discard the water layer, Removal of the solvent affords N-protecting group-4-isobutoxybenzylamine.

在上述制备方法中所用溶剂包括但不限于DMF、DMA、乙醇、乙腈,优选溶剂:DMF,N-保护基-4-羟基苄胺与溶剂的比例为1:2~10(m/v);The solvent used in the above preparation method includes but not limited to DMF, DMA, ethanol, acetonitrile, preferred solvent: DMF, the ratio of N-protecting group-4-hydroxybenzylamine to solvent is 1:2~10(m/v);

萃取试剂为二氯甲烷、乙酸乙酯、甲苯、二氧六环,优选试剂为二氯甲烷;The extraction reagent is dichloromethane, ethyl acetate, toluene, dioxane, and the preferred reagent is dichloromethane;

缚酸剂为无水碳酸钠、无水碳酸钾、1,8-二氮杂二环十一碳-7-烯(DBU),优选催化剂为无水碳酸钾。The acid-binding agent is anhydrous sodium carbonate, anhydrous potassium carbonate, 1,8-diazabicycloundec-7-ene (DBU), and the preferred catalyst is anhydrous potassium carbonate.

(3)制备式IV所述的4-异丁氧基苄胺:(3) 4-isobutoxybenzylamine described in the preparation formula IV:

将N-保护基-4-异丁氧基苄胺与脱保护试剂按摩尔比1:(3-10),优选比例1:(3-4),加入溶剂中,-25~78℃,优选温度40~78℃下反应3-8h,制得4-异丁氧基苄胺。Add N-protecting group-4-isobutoxybenzylamine and deprotection reagent in a molar ratio of 1:(3-10), preferably 1:(3-4), into the solvent, -25~78°C, preferably React at a temperature of 40-78°C for 3-8 hours to obtain 4-isobutoxybenzylamine.

所述的溶剂为甲醇、乙醇、异丙醇、DMF、二氯甲烷优选溶剂为乙醇;Described solvent is methanol, ethanol, Virahol, DMF, methylene dichloride, and the preferred solvent is ethanol;

脱保护试剂为氢氧化钠、氢氧化钾,甲醇钠、乙醇钠、氢化钠、水合肼、三氟乙酸、盐酸,优选碱性脱保护试剂氢氧化钾,酸性脱保护试剂三氟乙酸。The deprotection reagent is sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, hydrazine hydrate, trifluoroacetic acid, hydrochloric acid, preferably alkaline deprotection reagent potassium hydroxide, and acidic deprotection reagent trifluoroacetic acid.

(4)制备式V所述的N-(4-异丁氧基苄基)氨基甲酸苯酯:(4) N-(4-isobutoxybenzyl) phenyl carbamate described in the preparation formula V:

将4-异丁氧基苄胺、氯甲酸苯酯与缚酸剂按照摩尔比1:(1.1-2):(1.2-3),优选比例1:(1.2-1.3):(1.5-2),加入溶剂中,-25~60℃,优选温度为0~25℃下反应1-3h,反应结束后,脱去溶剂,残留物水洗,固体抽滤,用精制试剂重结晶,得N-(4-异丁氧基苄基)氨基甲酸苯酯。4-isobutoxybenzylamine, phenyl chloroformate and acid binding agent according to the molar ratio 1:(1.1-2):(1.2-3), the preferred ratio 1:(1.2-1.3):(1.5-2) , added to the solvent, and reacted at -25 to 60°C, preferably at a temperature of 0 to 25°C, for 1-3h. After the reaction, the solvent was removed, the residue was washed with water, the solid was suction filtered, and recrystallized with a refining reagent to obtain N-( 4-isobutoxybenzyl)phenylcarbamate.

在上述制备方法中所用溶剂包括但不限于二氯甲烷、二氧六环、四氢呋喃、甲苯、甲醇、乙醇、异丙醇、乙腈,优选溶剂为二氯甲烷,4-异丁氧基苄胺与溶剂的比例为1:2~8(m/v);The solvent used in the above-mentioned preparation method includes but not limited to dichloromethane, dioxane, tetrahydrofuran, toluene, methanol, ethanol, isopropanol, acetonitrile, the preferred solvent is dichloromethane, 4-isobutoxybenzylamine and The ratio of solvent is 1:2~8(m/v);

缚酸剂为三乙胺、吡啶、碳酸氢钠、碳酸氢钾、无水碳酸钠、无水碳酸钾、氢氧化钠、氢氧化钾,优选缚酸剂为无水碳酸钾;The acid-binding agent is triethylamine, pyridine, sodium bicarbonate, potassium bicarbonate, anhydrous sodium carbonate, anhydrous potassium carbonate, sodium hydroxide, potassium hydroxide, preferably the acid-binding agent is anhydrous potassium carbonate;

精制试剂为甲醇、乙醇,优选试剂为甲醇。The refining reagents are methanol and ethanol, and the preferred reagent is methanol.

(5)制备式VII所述N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐:(5) Tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea described in the preparation formula VII :

将N-(4-氟苄基)-1-甲基-4-哌啶胺、N-(4-异丁氧基苄基)氨基甲酸苯酯与酒石酸按照摩尔 比1:(1.1-1.5):(0.5-1),优选比例1:(1.2-1.3):(0.5-0.52),将上述N-(4-氟苄基)-1-甲基-4-哌啶胺与N-(4-异丁氧基苄基)氨基甲酸苯酯加入溶剂中,25~100℃,优选温度为65~78℃反应3-12h,反应结束后,温度降至45~40℃,该温下加入酒石酸固体搅拌2-4小时,反应停止并降至室温析晶5-9小时,抽滤,用精致试剂重结晶,将晶体抽滤,制得所述N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐。N-(4-fluorobenzyl)-1-methyl-4-piperidinamine, N-(4-isobutoxybenzyl)phenyl carbamate and tartaric acid in a molar ratio of 1:(1.1-1.5) :(0.5-1), preferred ratio 1:(1.2-1.3):(0.5-0.52), the above-mentioned N-(4-fluorobenzyl)-1-methyl-4-piperidinamine and N-(4 - Isobutoxybenzyl) phenyl carbamate is added to the solvent, and the reaction temperature is 25-100°C, preferably 65-78°C, for 3-12h. After the reaction, the temperature drops to 45-40°C, and tartaric acid is added at this temperature Stir the solid for 2-4 hours, stop the reaction and drop to room temperature to crystallize for 5-9 hours, filter with suction, recrystallize with refined reagents, and filter the crystals with suction to obtain the N-(4-fluorobenzyl)-N- Tartrate salt of (1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea.

在上述制备方法中所用溶剂包括但不限于甲醇、乙醇、异丙醇、甲苯、乙腈,优选溶剂为乙醇,N-(4-氟苄基)-1-甲基-4-哌啶胺与溶剂的比例为1:2~10(m/v);The solvent used in the above-mentioned preparation method includes but not limited to methanol, ethanol, isopropanol, toluene, acetonitrile, the preferred solvent is ethanol, N-(4-fluorobenzyl)-1-methyl-4-piperidinamine and solvent The ratio is 1:2~10(m/v);

精制试剂为无水甲醇、无水乙醇、异丙醇,优选试剂无水乙醇。Refining reagents are absolute methanol, absolute ethanol, isopropanol, preferably absolute ethanol.

整条合成路线表示如下:The whole synthetic route is expressed as follows:

本发明的优点在于:本发明所设计的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐合成工艺而言,具有原料易得、操作简便、收率较高、成本较低、三废较少、安全性高的特点,适合工业生产。The advantage of the present invention is: N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea designed in the present invention As far as the tartrate synthesis process is concerned, it has the characteristics of easy-to-obtain raw materials, simple operation, high yield, low cost, less three wastes, and high safety, and is suitable for industrial production.

具体实施方式detailed description

本发明所要合成的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐及其中间体N-保护基-4-羟基苄胺、N-保护基-4-异丁氧基苄胺、4-异丁氧基苄胺和N-(4-异丁氧基苄基)氨基甲酸苯酯可按下列步骤进行:The tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea and its intermediate Body N-protecting group-4-hydroxybenzylamine, N-protecting group-4-isobutoxybenzylamine, 4-isobutoxybenzylamine and N-(4-isobutoxybenzyl)carbamate benzene Esters can be carried out as follows:

实施例1,以乙氧羰基作保护基团Embodiment 1, with ethoxycarbonyl as protecting group

1)N-(4-羟基苄基)氨基甲酸乙酯1) N-(4-hydroxybenzyl) ethyl carbamate

于室温将4-羟基苄胺(20g)和碳酸氢钠(16g)加入到二氯甲烷(100ml)中搅拌,在0℃ 到20℃用1小时将氯甲酸乙酯(19.4g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌2小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用二氯甲烷(50ml×2)洗涤滤饼。滤液用5%稀盐酸(36ml×2)洗涤,再用水(75ml×2)洗涤,分层后弃去水层,有机层干燥。30℃到40℃减压回收溶剂,得到红色固体粗品(30g),固体用甲苯(45ml×2)洗涤。将产物过滤,40℃真空干燥3h,得到淡黄色固体(29.1g),收率81.1%,mp:62~64℃,ESI-MS m/z:196[M+H]+,218[M+Na]+. 4-Hydroxybenzylamine (20 g) and sodium bicarbonate (16 g) were added to dichloromethane (100 ml) and stirred at room temperature, and ethyl chloroformate (19.4 g) was added dropwise to in suspension. After the addition was complete, the mixture was stirred at 20°C to 25°C for 2 hours, starting material remaining by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with dichloromethane (50ml x 2). The filtrate was washed with 5% dilute hydrochloric acid (36ml×2), and then washed with water (75ml×2). After separating the layers, the aqueous layer was discarded, and the organic layer was dried. The solvent was recovered under reduced pressure at 30°C to 40°C to obtain a crude red solid (30g), which was washed with toluene (45ml×2). The product was filtered and vacuum-dried at 40°C for 3 hours to obtain a light yellow solid (29.1g), yield 81.1%, mp: 62-64°C, ESI-MS m/z: 196[M+H] + , 218[M+ Na] +.

2)N-(4-异丁氧基苄基)氨基甲酸乙酯2) N-(4-isobutoxybenzyl) ethyl carbamate

于15℃到25℃将N-(4-羟基苄基)氨基甲酸乙酯(47g)溶解在二甲基甲酰胺(250ml)中,然后在<30℃分批加入无水碳酸钾(50g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(40g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(100ml×2)洗涤滤饼。减压回收溶剂,残余物用二氯甲烷(300ml)稀释,用5%NaOH(50ml×2)洗涤二氯甲烷溶液,然后水(100ml×2)洗涤,水层弃去,二氯甲烷溶液在50℃下减压回收,残余固体加入正己烷(100ml)加热至60℃搅拌,固体溶解后冷却至40℃,加入10g活性炭粉末,重新加热至60℃搅拌30分钟,趁热过滤不溶物,滤液在搅拌下冷却至10℃(约在30℃时析晶)并静置3小时,将产物过滤并用冷正己烷(50ml×2)洗涤滤饼,30℃真空干燥5小时,得到淡黄色絮状固体(46.2g),收率76.6%,mp:39~40℃,ESI-MS m/z:252[M+H]+,274[M+Na]+. Dissolve ethyl N-(4-hydroxybenzyl)carbamate (47g) in dimethylformamide (250ml) at 15°C to 25°C, then add anhydrous potassium carbonate (50g) in portions at <30°C , and the suspension was heated to 78°C to 82°C. Isobutane bromide (40 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (100ml×2). The solvent was recovered under reduced pressure, the residue was diluted with dichloromethane (300ml), and the dichloromethane solution was washed with 5% NaOH (50ml×2), then washed with water (100ml×2), the aqueous layer was discarded, and the dichloromethane solution was Recover under reduced pressure at 50°C, add n-hexane (100ml) to the residual solid, heat to 60°C and stir, dissolve the solid and cool to 40°C, add 10g of activated carbon powder, reheat to 60°C and stir for 30 minutes, filter the insoluble matter while it is hot, and the filtrate Cool to 10°C under stirring (crystallization at about 30°C) and let stand for 3 hours, filter the product and wash the filter cake with cold n-hexane (50ml×2), and vacuum dry at 30°C for 5 hours to obtain light yellow flocculent Solid (46.2g), yield 76.6%, mp: 39~40℃, ESI-MS m/z: 252[M+H] + , 274[M+Na] +.

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于40℃到45℃将氢氧化钾(15g)溶解在乙醇(50ml)中,然后加入N-(4-异丁氧基苄基)氨基甲酸乙酯(17g)固体,将溶液加热至78℃搅拌8小时,用TLC检测原料剩余。反应完成后,50℃减压回收乙醇,将二氯甲烷(75ml)加入到残余物中,室温搅拌10分钟,过滤不溶物,于30℃减压浓缩,得到油状氨基碱9.9g,收率82%,ESI-MS m/z:180[M+H]+,202[M+Na]+. Dissolve potassium hydroxide (15g) in ethanol (50ml) at 40°C to 45°C, then add N-(4-isobutoxybenzyl) ethyl carbamate (17g) as a solid, and heat the solution to 78°C Stir for 8 hours and check for remaining starting material by TLC. After the reaction was completed, ethanol was recovered under reduced pressure at 50°C, dichloromethane (75ml) was added to the residue, stirred at room temperature for 10 minutes, the insoluble matter was filtered, and concentrated under reduced pressure at 30°C to obtain 9.9g of oily amino base, yield 82 %, ESI-MS m/z: 180[M+H] + , 202[M+Na] +.

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(5g)油状液体溶解二氯甲烷(10ml)中,然后添加无水碳酸钾(5g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用0.5小时将氯甲酸苯酯(4.8g)滴加到该悬浮液中。添加结束后,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以二氯甲烷(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(8.1g)粗品,加入甲醇(10ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(5ml*2)洗涤滤饼。于60℃真空干燥2小时,得到5.9g白色固体纯品,收率71%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve 4-isobutoxybenzylamine (5 g) oily liquid which has deprotected group in dichloromethane (10 ml) at room temperature, then add anhydrous potassium carbonate (5 g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (4.8 g) was added dropwise to the suspension at 0°C to 10°C over 0.5 hours. After the addition was complete, the remaining starting material was detected by TLC. After the reaction, remove the inorganic salts by filtration, wash the filter cake with dichloromethane (30ml*2), wash the filtrate with 10% HCl (100ml*2), separate the layers to obtain an organic layer, wash with water (100ml*2), and dry Finally, the solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (8.1 g), which was added with methanol (10 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (5ml*2). Vacuum dried at 60°C for 2 hours to obtain 5.9g of pure white solid, yield 71%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(14.8g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(10g)溶解在无水乙醇(20ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。N-(4-isobutoxybenzyl)phenylcarbamate (14.8g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (10g) were dissolved in the In water ethanol (20ml), heated to reflux and stirred for 3 hours, the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(3.38g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(150ml) 加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(16.2g),收率84.1%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (3.38g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C for 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (16.2g), yield 84.1%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例2,以甲氧羰基作保护基团Embodiment 2, with methoxycarbonyl as protecting group

1)N-(4-羟基苄基)氨基甲酸甲酯1) Methyl N-(4-hydroxybenzyl)carbamate

于室温(25℃,下同)将4-羟基苄胺(15g)和碳酸氢钠(15g)加入到二氯甲烷(90ml)中搅拌,在-25℃到0℃用1小时将氯甲酸甲酯(13.8g)滴加到悬浮液中。添加结束后,将该混合物在-25℃下搅拌2小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用二氯甲烷(50ml×2)洗涤滤饼。滤液用5%稀盐酸(36ml×2)洗涤,再用水(75ml×2)洗涤,分层后弃去水层,有机层干燥。40℃减压回收溶剂,得到红色液体,50℃真空干燥3h,得到红色油状液体23.3g,收率:81%,ESI-MS m/z:182[M+H]+,204[M+Na]+ Add 4-hydroxybenzylamine (15g) and sodium bicarbonate (15g) into dichloromethane (90ml) at room temperature (25°C, the same below) and stir, and dichloroformate formaldehyde at -25°C to 0°C for 1 hour The ester (13.8 g) was added dropwise to the suspension. After the addition was complete, the mixture was stirred at -25°C for 2 hours and the remaining starting material was checked by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with dichloromethane (50ml x 2). The filtrate was washed with 5% dilute hydrochloric acid (36ml×2), and then washed with water (75ml×2). After separating the layers, the aqueous layer was discarded, and the organic layer was dried. The solvent was recovered under reduced pressure at 40°C to obtain a red liquid, which was dried under vacuum at 50°C for 3 hours to obtain 23.3g of a red oily liquid, yield: 81%, ESI-MS m/z: 182[M+H] + , 204[M+Na ] +

2)N-(4-异丁氧基苄基)氨基甲酸甲酯2) Methyl N-(4-isobutoxybenzyl)carbamate

于室温(25℃)将N-(4-羟基苄基)氨基甲酸甲酯(12g)溶解在二甲基乙酰胺(24ml)中,然后在<30℃分批加入无水碳酸钾(11g),并将该悬浮液加热到50℃到55℃。于55℃用2小时将溴代异丁烷(12g)滴加到悬浮液中。添加结束后,将该混合物在55℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收溶剂。残余液用二氯甲烷(150ml)稀释,用5%NaOH(30ml×2)洗涤二氯甲烷溶液,然后水(50ml×2)洗涤,水层弃去,二氯甲烷溶液在50℃下减压回收,得到的黄色液体在50℃真空干燥3小时,得到黄色油状液体(12.4g),收率:77.8%,ESI-MS m/z:238[M+H]+,260[M+Na]+ Dissolve methyl N-(4-hydroxybenzyl)carbamate (12g) in dimethylacetamide (24ml) at room temperature (25°C), then add anhydrous potassium carbonate (11g) in portions at <30°C , and the suspension was heated to 50°C to 55°C. Isobutane bromide (12 g) was added dropwise to the suspension at 55°C over 2 hours. After the addition was complete, the mixture was stirred at 55° C. for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (50ml×2). The solvent was recovered under reduced pressure. The residue was diluted with dichloromethane (150ml), and the dichloromethane solution was washed with 5% NaOH (30ml×2), then washed with water (50ml×2), the aqueous layer was discarded, and the dichloromethane solution was decompressed at 50°C Recovery, the obtained yellow liquid was vacuum-dried at 50°C for 3 hours to obtain a yellow oily liquid (12.4g), yield: 77.8%, ESI-MS m/z: 238[M+H] + , 260[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于40℃到45℃将氢氧化钾(13g)溶解在乙醇(40ml)中,然后加入N-(4-异丁氧基苄基)氨基甲酸甲酯(14g)固体,将溶液加热至78℃搅拌2小时,用TLC检测原料剩余。反应完成后,50℃减压回收乙醇,将二氯甲烷(60ml)加入到残余物中,室温搅拌10分钟,过滤不溶物,水洗(30ml*2)分层,于30℃减压浓缩溶剂,得到油状氨基碱8.8g,收率83%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Potassium hydroxide (13g) was dissolved in ethanol (40ml) at 40°C to 45°C, then solid methyl N-(4-isobutoxybenzyl)carbamate (14g) was added, and the solution was heated to 78°C Stir for 2 hours and check for remaining starting material by TLC. After the reaction was completed, ethanol was recovered under reduced pressure at 50°C, dichloromethane (60ml) was added to the residue, stirred at room temperature for 10 minutes, the insoluble matter was filtered, washed with water (30ml*2) to separate layers, and the solvent was concentrated under reduced pressure at 30°C. 8.8 g of oily amino base was obtained, the yield was 83%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(8g)油状液体溶解二氧六环(24ml)中,然后添加无水碳酸钠(8g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(8.4g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,再加热至60℃搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以二氧六环(20ml*2)洗涤滤饼,滤液用10%HCl(20ml*2)洗涤,分层得到有机层用水(20ml*2)洗涤,经干燥后,60℃减压回收溶剂,得到白色固体(23g)粗品,加入甲醇(30ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(10ml*2)洗涤滤饼。于60℃真空干燥2小时,得到10g白色固体纯品,收率75%,mp:99.1~99.4℃;ESI-MS m/z:300[M+H]+,322[M+Na]+ Dissolve the oily liquid of 4-isobutoxybenzylamine (8g) deprotected in dioxane (24ml) at room temperature, then add anhydrous sodium carbonate (8g), and cool the suspension to 0°C to 10°C. °C, and phenyl chloroformate (8.4 g) was added dropwise to the suspension at 0 °C to 10 °C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, then heated to 60°C and stirred for 1 hour, and the residual starting material was checked by TLC. After the reaction was finished, the inorganic salts were removed by filtration, the filter cake was washed with dioxane (20ml*2), the filtrate was washed with 10% HCl (20ml*2), the layers were separated to obtain an organic layer, washed with water (20ml*2), and washed with water (20ml*2). After drying, the solvent was recovered under reduced pressure at 60°C to obtain a crude white solid (23g), which was added with methanol (30ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (10ml*2). Vacuum dried at 60°C for 2 hours to obtain 10 g of pure white solid, yield 75%, mp: 99.1~99.4°C; ESI-MS m/z: 300[M+H] + , 322[M+Na] +

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(12.9g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(8g)溶解在甲苯(30ml)中,加热至回流并搅拌12小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的甲苯溶液。N-(4-isobutoxybenzyl)phenyl carbamate (12.9g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (8g) were dissolved in toluene at room temperature (30ml), heated to reflux and stirred for 12 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, a toluene solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea was obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

脱去甲苯溶剂,加入30ml无水乙醇,在40℃到45℃用30分钟将酒石酸固体(3.24g)添加到乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(150ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(13.7g),收率89.4%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1H NMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7and4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Remove the toluene solvent, add 30ml of absolute ethanol, and add tartaric acid solid (3.24g) into the ethanol solution (yield 100%, calculated as piperidinamine) at 40°C to 45°C for 30 minutes, and stir at this temperature After 2 hours, the solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (13.7g), yield 89.4%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 H NMR (400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7and4.5Hz, 4H, Ar-H), 6.83 (d, J=8.6Hz, 2H, Ar-H), 4.42 (s, 2H, CH 2 ), 4.19 (d, J=5.5Hz, 2H, CH 2 ), 4.02 ( s,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41– 2.29(m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz , 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35 , 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53 ; 780.1, 732.4.

实施例3,以叔丁氧羰基作保护基团Example 3, using tert-butoxycarbonyl as a protecting group

1)N-(4-羟基苄基)-氨基甲酸叔丁酯1) N-(4-hydroxybenzyl)-tert-butyl carbamate

于室温将4-羟基苄胺(20g)和碳酸氢钾(22g)加入到四氢呋喃(60ml)与水(15ml)中搅拌,在0℃到20℃用1小时将二碳酸二叔丁酯(46.1g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌24小时,用TLC检测起始原料剩余。反应完成后,将固体抽滤,用四氢呋喃(30ml×2)洗涤滤饼,将固体用5%稀盐酸(36ml×2)洗涤,将固体过滤,用水(50ml×2)洗涤,抽滤。固体在60℃真空干燥5小时,得到灰白色粉末14.7g,收率:72.1%,mp:105~107℃,ESI-MS m/z:224[M+H]+,246[M+Na]+ 4-Hydroxybenzylamine (20g) and potassium bicarbonate (22g) were added to tetrahydrofuran (60ml) and water (15ml) at room temperature and stirred, di-tert-butyl dicarbonate (46.1 g) dropwise into the suspension. After the addition was complete, the mixture was stirred at 20°C to 25°C for 24 hours, starting material remaining by TLC. After the reaction was complete, the solid was filtered with suction, the filter cake was washed with tetrahydrofuran (30ml×2), the solid was washed with 5% dilute hydrochloric acid (36ml×2), the solid was filtered, washed with water (50ml×2), and filtered with suction. The solid was dried under vacuum at 60°C for 5 hours to obtain 14.7g of off-white powder, yield: 72.1%, mp: 105-107°C, ESI-MS m/z: 224[M+H] + , 246[M+Na] +

2)N-(4-异丁氧基苄基)氨基甲酸叔丁酯2) tert-butyl N-(4-isobutoxybenzyl)carbamate

于室温将N-(4-羟基苄基)-氨基甲酸叔丁酯(25g)溶解在四氢呋喃(75ml)中,然后在<30℃分批加入无水碳酸钾(23g),并将该悬浮液加热到60℃。于60℃用2小时将溴代异丁烷(23g)滴加到悬浮液中。添加结束后,将该混合物在60℃-65℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收溶剂。残余液体倾入100ml水中,将析出固体抽滤,滤饼用5%NaOH(30ml×2)洗涤,然后水(30ml×2)洗涤,得到固体加入甲苯(60ml)加热至60℃搅拌溶解,然后在搅拌下冷却至10℃到15℃并静置10小时,将析出的淡黄色晶体过滤,用冷甲苯(15ml*2)洗涤,在45℃真空干燥5小时,得到棕色片状晶体(19.7g),收率:70.1%,mp:59~61℃,ESI-MS m/z:280[M+H]+,302[M+Na]+ Dissolve N-(4-hydroxybenzyl)-tert-butyl carbamate (25g) in tetrahydrofuran (75ml) at room temperature, then add anhydrous potassium carbonate (23g) in portions at <30°C, and dissolve the suspension Heat to 60°C. Bromoisobutane (23 g) was added dropwise to the suspension at 60°C over 2 hours. After the addition was complete, the mixture was stirred at 60°C-65°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (50ml×2). The solvent was recovered under reduced pressure. Pour the residual liquid into 100ml of water, filter the precipitated solid with suction, wash the filter cake with 5% NaOH (30ml×2), then wash with water (30ml×2), and add toluene (60ml) to the solid to be heated to 60°C and stir to dissolve, then Cool to 10°C to 15°C under stirring and let stand for 10 hours, filter the precipitated pale yellow crystals, wash with cold toluene (15ml*2), and vacuum dry at 45°C for 5 hours to obtain brown flaky crystals (19.7g ), yield: 70.1%, mp: 59~61℃, ESI-MS m/z: 280[M+H] + , 302[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于室温将N-(4-异丁氧基苄基)氨基甲酸叔丁酯20g溶解在二氯甲烷(200ml)中,然后在-25-0℃,将三氟乙酸(160ml)滴加至溶液中,滴加完成后转至室温搅拌3小时,用TLC检测原料剩余。反应完成后,将溶液PH调至碱性,并用水(50ml*2)洗分层,30℃减压浓 缩,得到油状氨基碱9.6g,收率74%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve 20 g of tert-butyl N-(4-isobutoxybenzyl) carbamate in dichloromethane (200 ml) at room temperature, then add trifluoroacetic acid (160 ml) dropwise to the solution at -25-0°C After the dropwise addition was completed, it was stirred at room temperature for 3 hours, and the remaining raw materials were detected by TLC. After the reaction was completed, the pH of the solution was adjusted to alkaline, and the layers were washed with water (50ml*2), and concentrated under reduced pressure at 30°C to obtain 9.6g of oily amino base, with a yield of 74%, ESI-MS m/z: 180[ M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(12g)油状液体溶解甲苯(40ml)中,然后添加三乙胺(9g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(14.6g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌3小时,通过TLC检测原料剩余。反应结束后,过滤除掉三乙胺盐酸盐,以甲苯(30ml*2)洗涤滤饼,滤液用10%HCl(30ml*2)洗涤,分层得到有机层用水(20ml*2)洗涤,经干燥后,60℃减压回收溶剂,得到白色固体(18g)粗品,加入乙醇(30ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷乙醇(10ml*2)洗涤滤饼。于60℃真空干燥2小时,得到14.4g白色固体纯品,收率78%,mp:98.6~99.1℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (12 g) deprotected at room temperature in toluene (40 ml), then add triethylamine (9 g), and cool the suspension to 0° C. to 10° C. Phenyl chloroformate (14.6 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 3 hours, the remaining starting material was checked by TLC. After the reaction, remove triethylamine hydrochloride by filtration, wash the filter cake with toluene (30ml*2), wash the filtrate with 10% HCl (30ml*2), separate the layers to obtain the organic layer, wash with water (20ml*2), After drying, the solvent was recovered under reduced pressure at 60°C to obtain a crude white solid (18 g), which was added with ethanol (30 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (10ml*2). Vacuum dried at 60°C for 2 hours to obtain 14.4g white solid pure product, yield 78%, mp: 98.6~99.1°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(21g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(12g)溶解在异丙醇(24ml)中,加热至回流并搅拌8小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (21g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (12g) in isopropyl Alcohol (24ml), heated to reflux and stirred for 8 hours, the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在60℃到65℃用30分钟将酒石酸固体(5.68g)添加到实施例5中制备的异丙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,有白色固体析出,将该溶液冷却至20℃到25℃,在此温度下静置3小时。将该产物过滤,并以冷异丙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(80ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(20.1g),收率87%,mp:135.5-137.5℃(文献133-135℃),ESI-MSm/z:428[M+H]+,450[M+Na]+,ESI-MS m/z:428[M+H]+,450[M+Na]+1H NMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (5.68g) was added to the isopropanol solution (100% yield, calculated as piperidinamine) prepared in Example 5 at 60°C to 65°C for 30 minutes, stirred at this temperature for 2 hours, A white solid precipitated out, and the solution was cooled to 20°C to 25°C and allowed to stand at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold isopropanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (80ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (20.1g), yield 87%, mp: 135.5-137.5°C (document 133-135°C), ESI-MSm/z: 428[M+H] + ,450[M+Na] + ,ESI-MS m/z:428[M+H] + ,450[M+Na] + ; 1 H NMR (400MHz, CDCl 3 )δ7.25 (dd, J=8.3 ,5.7Hz,2H,Ar-H),7.11(dt,J=8.7and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H , CH 2 ), 4.19 (d, J=5.5Hz, 2H, CH 2 ), 4.02 (s, 1H, CH), 3.70 (d, J=6.5Hz, 2H, CH 2 ), 2.98 (d, J= 11.1Hz, 2H, CH 2 ), 2.56–2.46 (m, 1H, NH), 2.41–2.29 (m, 4H, CH 2 ), 1.99 (dp, J=13.3, 6.6Hz, 2H, CH 2 ), 1.73 (q, J=12.3Hz, 2H, CH 2 ), 1.51 (d, J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 )δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm -1 ):3425.1, 2930.3, 1693.3, 1647.6, 1383.9, 1263.9, 1074.3, 856.6, 834.2, 780.1, 732.4.

实施例4,以乙酰基作保护基团Embodiment 4, with acetyl group as protecting group

1)N-(4-羟基苄基)乙酰胺1) N-(4-hydroxybenzyl)acetamide

于室温将4-羟基苄胺(25g)和碳酸氢钠(31g)加入到甲苯(50ml)中搅拌,在0℃到20℃用1小时将乙酸酐(29.1g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌0.5小时,用TLC检测起始原料剩余。反应完成后,将固体抽滤,用二氯甲烷(25ml×2)洗涤滤饼,将固体用5%稀盐酸(45ml×2)洗涤,调PH至3-4,将固体过滤,用水(40ml×2)洗涤,得到白色固体。60℃真空干燥5小时,得到白色固体32.7g,收率:81.2%,mp:135~137℃,ESI-MS m/z:166[M+H]+,188[M+Na]+ 4-Hydroxybenzylamine (25g) and sodium bicarbonate (31g) were added to toluene (50ml) and stirred at room temperature, and acetic anhydride (29.1g) was added dropwise to the suspension at 0°C to 20°C over 1 hour. After the addition was complete, the mixture was stirred at 20°C to 25°C for 0.5 hours and the remaining starting material was checked by TLC. After the reaction was completed, the solid was suction filtered, the filter cake was washed with dichloromethane (25ml×2), the solid was washed with 5% dilute hydrochloric acid (45ml×2), the pH was adjusted to 3-4, the solid was filtered, and water (40ml ×2) washing to obtain a white solid. Vacuum dried at 60°C for 5 hours to obtain 32.7g of white solid, yield: 81.2%, mp: 135~137°C, ESI-MS m/z: 166[M+H] + , 188[M+Na] +

2)N-(4-异丁氧基苄基)乙酰胺2) N-(4-isobutoxybenzyl)acetamide

于室温将N-(4-羟基苄基)乙酰胺(10g)溶解在乙腈(30ml)中,然后在<30℃分批加入无水碳酸钠(11g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(12g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC 检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钠盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收溶剂。残余液体倾入100ml水中,将析出固体抽滤,滤饼用5%NaOH(30ml×2)洗涤,然后水(30ml×2)洗涤,得到固体加入甲苯(60ml)加热至60℃搅拌30分钟,滤液在搅拌下冷却至15℃到20℃并静置5小时,将析出的淡黄色晶体过滤,用冷甲苯(15ml*2),洗涤,在45℃真空干燥5小时,得到淡黄色固体(7.75g),收率:50.3%,mp:53~55℃,ESI-MS m/z:222[M+H]+,244[M+Na]+ N-(4-Hydroxybenzyl)acetamide (10 g) was dissolved in acetonitrile (30 ml) at room temperature, then anhydrous sodium carbonate (11 g) was added in portions at <30 °C, and the suspension was heated to 78 °C to 82°C. Isobutane bromide (12 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess sodium salt, and the filter cake was washed with dichloromethane (50ml×2). The solvent was recovered under reduced pressure. Pour the residual liquid into 100ml of water, filter the precipitated solid with suction, wash the filter cake with 5% NaOH (30ml×2), and then wash with water (30ml×2) to obtain the solid, add toluene (60ml) and heat to 60°C for 30 minutes, The filtrate was cooled to 15°C to 20°C under stirring and allowed to stand for 5 hours. The precipitated pale yellow crystals were filtered, washed with cold toluene (15ml*2), and dried in vacuo at 45°C for 5 hours to obtain a pale yellow solid (7.75 g), yield: 50.3%, mp: 53~55℃, ESI-MS m/z: 222[M+H] + , 244[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于室温将水合肼(80ml)溶解在甲醇(100ml)中,然后加入N-(4-异丁氧基苄基)乙酰胺(10g)固体,将溶液加热至回流温度搅拌8小时,用TLC检测原料剩余。反应完成后,80℃减压回收溶剂,将二氯甲烷(80ml)加入到残余物中,水(30ml*2)洗,然后于30℃减压浓缩,得到油状氨基碱5.3g,收率65%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve hydrazine hydrate (80ml) in methanol (100ml) at room temperature, then add N-(4-isobutoxybenzyl)acetamide (10g) solid, the solution is heated to reflux temperature and stirred for 8 hours, detected by TLC Raw material remaining. After the reaction was completed, the solvent was recovered under reduced pressure at 80°C, dichloromethane (80ml) was added to the residue, washed with water (30ml*2), and then concentrated under reduced pressure at 30°C to obtain 5.3g of oily amino base with a yield of 65 %, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(15g)油状液体溶解四氢呋喃(75ml)中,然后添加碳酸氢钠(15g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(19.6g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,再加热至60℃搅拌10小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以四氢呋喃(30ml*2)洗涤滤饼,滤液用10%HCl(50ml*2)洗涤,分层得到有机层用水(20ml*2)洗涤,经干燥后,60℃减压回收溶剂,得到白色固体(25g)粗品,加入甲醇(50ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到15.8g白色固体纯品,收率62%,mp:97.8~98.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (15 g) deprotected at room temperature in tetrahydrofuran (75 ml), then add sodium bicarbonate (15 g), and cool the suspension to 0° C. to 10° C., and in Phenyl chloroformate (19.6 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, then heated to 60°C and stirred for 10 hours, and the residual starting material was checked by TLC. After the reaction, remove the inorganic salt by filtration, wash the filter cake with tetrahydrofuran (30ml*2), wash the filtrate with 10% HCl (50ml*2), separate the layers to obtain the organic layer, wash with water (20ml*2), and after drying, The solvent was recovered under reduced pressure at 60°C to obtain a crude white solid (25 g), which was added with methanol (50 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 15.8g of pure white solid, yield 62%, mp: 97.8~98.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(37.7g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(20g)溶解在甲醇(60ml)中,加热至回流并搅拌6小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (37.7g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (20g) in methanol at room temperature (60ml), heated to reflux and stirred for 6 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(4.5g)添加到实施例5中制备的甲醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却0℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水甲醇(150ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置24小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(28.2g),收率62%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1H NMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (4.5 g) was added to the methanol solution (yield 100%, calculated as piperidine amine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 0°C and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). The crude product was obtained, and the wet product was heated to reflux with anhydrous methanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C for 1 hour, and stood at this temperature for 24 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (28.2g), yield 62%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 H NMR (400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7and 4.5Hz, 4H, Ar-H), 6.83 (d, J=8.6Hz, 2H, Ar-H), 4.42 (s, 2H, CH 2 ), 4.19 (d, J=5.5Hz, 2H, CH 2 ), 4.02 ( s,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41– 2.29(m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz , 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35 , 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53 ; 780.1, 732.4.

实施例5,以甲酰基作保护基团Embodiment 5, with formyl as protecting group

1)N-(4-羟基苄基)甲酰胺1) N-(4-hydroxybenzyl) formamide

于室温将4-羟基苄胺(20g)和碳酸氢钠(27g)加入到甲苯(60ml)中搅拌,在0℃到20℃用1小时将新制甲乙酐(21.5g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌2小时,然后加热至60℃搅拌1小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用甲苯(30ml×2)洗涤滤饼。滤液用5%稀盐酸(35ml×2)洗涤,再用水(45ml×2)洗涤分层,有机层干燥。30℃到40℃减压回收溶剂,得到红色油状物,20℃到25℃放置3小时得到黄色固体,固体过滤并用二氯甲烷(30ml)洗涤,60℃真空干燥3时,得到淡黄色固体20.6g,收率:60.0%,mp:122~124℃,ESI-MS m/z:152[M+H]+,174[M+Na]+ 4-Hydroxybenzylamine (20g) and sodium bicarbonate (27g) were added to toluene (60ml) at room temperature and stirred, and fresh formic anhydride (21.5g) was added dropwise to the suspension at 0°C to 20°C for 1 hour . After the addition was complete, the mixture was stirred at 20°C to 25°C for 2 hours, then heated to 60°C and stirred for 1 hour, starting material remaining by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with toluene (30ml x 2). The filtrate was washed with 5% dilute hydrochloric acid (35ml×2), and the layers were washed with water (45ml×2), and the organic layer was dried. The solvent was recovered under reduced pressure at 30°C to 40°C to obtain a red oil, which was left at 20°C to 25°C for 3 hours to obtain a yellow solid, which was filtered and washed with dichloromethane (30ml), dried under vacuum at 60°C for 3 hours to obtain a pale yellow solid 20.6 g, yield: 60.0%, mp: 122~124℃, ESI-MS m/z: 152[M+H] + , 174[M+Na] +

2)N-(4-异丁氧基苄基)甲酰胺2) N-(4-isobutoxybenzyl) formamide

于室温将N-(4-羟基苄基)甲酰胺(12g)溶解在二甲基甲酰胺(50ml)中,然后在<30℃分批加入无水碳酸钾(15g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(17g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(20ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余液体倾入100ml水中,将析出固体抽滤,滤饼用5%NaOH(30ml×2)洗涤,然后水(30ml×2)洗涤,得到固体加入乙腈(50ml)加热至80℃溶解并搅拌30分钟,溶液在搅拌下冷却至15℃到20℃并静置5小时,将析出的白色晶体过滤,用冷甲苯(15ml*2),洗涤,在45℃真空干燥5小时,得白色粉末固体(13.9g),收率:70.0%,mp:78~81℃,ESI-MS m/z:208[M+H]+,230[M+Na]+ Dissolve N-(4-hydroxybenzyl)formamide (12g) in dimethylformamide (50ml) at room temperature, then add anhydrous potassium carbonate (15g) in portions at <30°C, and dissolve the suspension Heat to 78°C to 82°C. Isobutane bromide (17 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (20ml×2). Dimethylformamide was recovered under reduced pressure. Pour the residual liquid into 100ml of water, filter the precipitated solid with suction, wash the filter cake with 5% NaOH (30ml×2), then wash with water (30ml×2), and add acetonitrile (50ml) to heat to 80°C to dissolve the solid and stir for 30 Minutes, the solution was cooled to 15°C to 20°C under stirring and allowed to stand for 5 hours, the precipitated white crystals were filtered, washed with cold toluene (15ml*2), and dried in vacuum at 45°C for 5 hours to obtain a white powder solid ( 13.9g), yield: 70.0%, mp: 78~81℃, ESI-MS m/z: 208[M+H] + ,230[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于40℃到45℃将氢氧化钠(20g)溶解在乙醇(40ml)中,然后加入N-(4-异丁氧基苄基)甲酰胺(19g)固体,将溶液在室温下搅拌5小时,用TLC检测原料剩余。反应完成后,50℃减压回收乙醇,将二氯甲烷(75ml)加入到残余物中,室温搅拌10分钟,过滤不溶物,然后于30℃减压浓缩,得到油状氨基碱12.3g,收率75%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve sodium hydroxide (20g) in ethanol (40ml) at 40°C to 45°C, then add N-(4-isobutoxybenzyl)formamide (19g) as a solid, and stir the solution at room temperature for 5 hours , The remaining starting material was detected by TLC. After the reaction was completed, ethanol was recovered under reduced pressure at 50°C, dichloromethane (75ml) was added to the residue, stirred at room temperature for 10 minutes, the insoluble matter was filtered, and then concentrated under reduced pressure at 30°C to obtain 12.3g of oily amino base, yield 75%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(13g)油状液体溶解二氯甲烷(65ml)中,然后添加无水碳酸钾(15g),将悬浮液冷却至-25℃到0℃,并在0℃到10℃用1小时将氯甲酸苯酯(18.1g)滴加到该悬浮液中。添加结束后,将该混合物冷至-25℃下搅拌2.5小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(25ml*2)洗涤滤饼,滤液用10%HCl(20ml*2)洗涤,分层得到有机层用水(20ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(23g)粗品,加入甲醇(50ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到18g白色固体纯品,收率83%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (13g) deprotected in dichloromethane (65ml) at room temperature, then add anhydrous potassium carbonate (15g), and cool the suspension to -25°C to 0 °C, and phenyl chloroformate (18.1 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was cooled to -25°C and stirred for 2.5 hours, starting material remaining by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (25ml*2), the filtrate was washed with 10% HCl (20ml*2), the layers were separated to obtain an organic layer, washed with water (20ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (23g), which was added with methanol (50ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 18g white solid pure product, yield 83%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(30.3g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(15g)溶解在乙醇(60ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (30.3g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (15g) in ethanol at room temperature (60ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(9.12g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(150ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。 过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(26g),收率90%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1H NMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (9.12g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (26g), yield 90%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 H NMR (400MHz, CDCl 3 )δ7.25 (dd, J=8.3, 5.7Hz, 2H, Ar-H), 7.11 (dt, J=8.7 and 4.5Hz, 4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例6,以苄氧羰基作保护基团Embodiment 6, using benzyloxycarbonyl as protecting group

1)N-(4-羟基苄基)氨基甲酸苄酯1) Benzyl N-(4-hydroxybenzyl)carbamate

于室温将4-羟基苄胺(10g)和三乙胺(14g)加入到乙腈(40ml)中搅拌,在0℃到20℃用1小时将氯甲酸苄酯(22.2g)滴加到悬浮液中。添加结束后,将该混合物在35℃到40℃搅拌2小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量三乙胺盐酸盐。减压除去溶剂,用二氯甲烷(20ml×2)稀释残余固体。滤液用5%稀盐酸(25ml×2)洗涤调酸,再用水(30ml×2)洗涤,分层后弃去水层,有机层干燥。30℃到40℃减压回收溶剂,得到红色固体,固体抽滤用甲苯洗涤,40℃真空干燥5小时,得到白色固体11.7g。收率:77.8%。mp:50~51℃ESI-MS m/z:258[M+H]+,280[M+Na]+ 4-Hydroxybenzylamine (10g) and triethylamine (14g) were added to acetonitrile (40ml) and stirred at room temperature, and benzyl chloroformate (22.2g) was added dropwise to the suspension at 0°C to 20°C for 1 hour middle. After the addition was complete, the mixture was stirred at 35°C to 40°C for 2 hours, and the remaining starting material was checked by TLC. After the reaction was completed, suction filtration was performed to remove excess triethylamine hydrochloride. The solvent was removed under reduced pressure, and the residual solid was diluted with dichloromethane (20ml×2). The filtrate was washed with 5% dilute hydrochloric acid (25ml×2) to adjust the acidity, and then washed with water (30ml×2). After separating the layers, the water layer was discarded, and the organic layer was dried. The solvent was recovered under reduced pressure at 30°C to 40°C to obtain a red solid. The solid was filtered with suction, washed with toluene, and dried under vacuum at 40°C for 5 hours to obtain 11.7 g of a white solid. Yield: 77.8%. mp:50~51℃ESI-MS m/z:258[M+H] + ,280[M+Na] +

2)N-(4-异丁氧基苄基)氨基甲酸苄酯2) Benzyl N-(4-isobutoxybenzyl)carbamate

于室温将N-(4-羟基苄基)氨基甲酸苄酯(18g)溶解在二甲基甲酰胺(90ml)中,然后在<30℃分批加入无水碳酸钾(19g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(14g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用二氯甲烷(150ml)稀释,用5%NaOH(30ml×2)洗涤二氯甲烷溶液,然后水(50ml×2)洗涤,水层弃去,二氯甲烷溶液在50℃下减压回收,残余固体加入甲醇(60ml)加热至60℃搅拌,固体溶解后冷却至50℃,加入8g活性炭粉末,重新加热至60℃搅拌30分钟,趁热过滤不溶物,滤液在搅拌下冷却至15℃到20℃(约在25℃时析晶)并静置5小时,将产物过滤并用冷甲醇(25ml×2)洗涤滤饼,30℃真空干燥5小时,得到黄色固体(14.7g),收率:83.4%,mp:38~39℃,ESI-MS m/z:314[M+H]+,336[M+Na]+ Benzyl N-(4-hydroxybenzyl)carbamate (18g) was dissolved in dimethylformamide (90ml) at room temperature, then anhydrous potassium carbonate (19g) was added in portions at <30°C, and the The suspension was heated to 78°C to 82°C. Isobutane bromide (14 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (50ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with dichloromethane (150ml), the dichloromethane solution was washed with 5% NaOH (30ml×2), then water (50ml×2), the aqueous layer was discarded, and the dichloromethane solution was decompressed at 50°C Recover, add methanol (60ml) to the residual solid and heat to 60°C and stir, dissolve the solid and cool to 50°C, add 8g of activated carbon powder, reheat to 60°C and stir for 30 minutes, filter the insoluble matter while it is hot, and cool the filtrate to 15°C under stirring ℃ to 20 ℃ (crystallization at about 25 ℃) and standing for 5 hours, the product was filtered and the filter cake was washed with cold methanol (25ml×2), and vacuum-dried at 30 ℃ for 5 hours to obtain a yellow solid (14.7g). Yield: 83.4%, mp: 38~39℃, ESI-MS m/z: 314[M+H] + ,336[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

将N-(4-异丁氧基苄基)氨基甲酸苄酯(5g)与5%Pd-C(0.3g)加入(30ml)乙醇中并通入氢气,室温下搅拌5小时,用TLC检测原料剩余。反应完毕将钯碳过滤,然后于50℃减压浓缩,得到油状氨基碱2.3g,收率63%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Add N-(4-isobutoxybenzyl)benzyl carbamate (5g) and 5% Pd-C (0.3g) into (30ml) ethanol and pass through hydrogen, stir at room temperature for 5 hours, and detect with TLC Raw material remaining. After the reaction was completed, the palladium carbon was filtered, and then concentrated under reduced pressure at 50°C to obtain 2.3 g of oily amino base, with a yield of 63%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(11g)油状液体溶解二氯甲烷(65ml)中,然后添加无水碳酸钾(13g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(13.4g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(40ml*2)洗涤,分层得到有机层用水(30ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(19g)粗品,加入甲醇(30ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到15.4g白色固体纯品,收率84%,mp:98.2~99.5℃, ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (11g) deprotected in dichloromethane (65ml) at room temperature, then add anhydrous potassium carbonate (13g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (13.4 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (40ml*2), the layers were separated to obtain an organic layer, washed with water (30ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (19 g), which was added with methanol (30 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 15.4g white solid pure product, yield 84%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + ,322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(16.3g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(11g)溶解在乙醇(55ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (16.3g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (11g) in ethanol at room temperature (55ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(7.43g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(100ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(19.3g),收率91%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (7.43g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (100ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (19.3g), yield 91%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例7,以笏甲氧羰基作保护基团Embodiment 7, with Wat methoxycarbonyl as protecting group

1)N-(4-羟基苄基)氨基甲酸笏甲酯1) Wat methyl N-(4-hydroxybenzyl) carbamate

于室温将4-羟基苄胺(15g)和碳酸氢钠(23g)加入到二氧六环(75ml)中搅拌,在0℃到20℃用1小时将芴甲氧羰酰氯(53.6g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌2小时,再升温至50℃搅拌1小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用二氧六环(30ml×2)洗涤滤饼。滤液用5%稀盐酸(30ml×2)洗涤,再用水(50ml×2)洗涤分层,有机层干燥。60℃到80℃减压回收溶剂,残余固体用乙醇(30ml)稀释并倾入300ml水中,将析出的固体进行抽滤并用乙二醇(50ml*2)洗涤滤饼,60℃真空干燥3h,得到白色固体17.1g,收率:85.7%,mp:144~146℃,ESI-MS m/z:346[M+H]+,368[M+Na]+ 4-Hydroxybenzylamine (15g) and sodium bicarbonate (23g) were added to dioxane (75ml) and stirred at room temperature, and fluorenylmethoxycarbonyl chloride (53.6g) was added dropwise at 0°C to 20°C for 1 hour added to the suspension. After the addition was complete, the mixture was stirred at 20°C to 25°C for 2 hours, then warmed up to 50°C and stirred for 1 hour, and the residual starting material was detected by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with dioxane (30ml x 2). The filtrate was washed with 5% dilute hydrochloric acid (30ml×2), and the layers were washed with water (50ml×2), and the organic layer was dried. Recover the solvent under reduced pressure at 60°C to 80°C, dilute the residual solid with ethanol (30ml) and pour it into 300ml of water, filter the precipitated solid with suction and wash the filter cake with ethylene glycol (50ml*2), and dry it in vacuum at 60°C for 3h. Obtained 17.1g of white solid, yield: 85.7%, mp: 144~146℃, ESI-MS m/z: 346[M+H] + , 368[M+Na] +

2)N-(4-异丁氧基苄基)氨基甲酸笏甲酯2) Wat methyl N-(4-isobutoxybenzyl) carbamate

于室温将N-(4-羟基苄基)氨基甲酸苄酯(12g)溶解在二甲基甲酰胺(70ml)中,然后在<30℃分批加入无水碳酸钾(19g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(14g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(30ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用二氯甲烷(300ml)稀释,用5%NaOH(25ml×2)洗涤二氯甲烷溶液,再用水(50ml×2)洗涤分层,水层弃去,溶剂在50-60℃下减压回收,残余固体加入异丙醚(20ml)加热至60℃搅拌,固体溶解后冷却至50℃,加入1g活性炭粉末,重新加热至60℃搅拌30分钟,趁热过滤不溶物,滤液在搅拌下冷却至15℃到20℃并静置10小时,将产物过滤并用冷异丙醚(5ml×2)洗涤滤饼,60℃真空干燥5小时,得到淡黄色固体(7.4g),收率:84.7%,mp:138~139℃,ESI-MSm/z:402[M+H]+,424[M+Na]+ Benzyl N-(4-hydroxybenzyl)carbamate (12 g) was dissolved in dimethylformamide (70 ml) at room temperature, then anhydrous potassium carbonate (19 g) was added in portions at <30° C., and the The suspension was heated to 78°C to 82°C. Isobutane bromide (14 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (30ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with dichloromethane (300ml), the dichloromethane solution was washed with 5% NaOH (25ml×2), and the layers were washed with water (50ml×2), the aqueous layer was discarded, and the solvent was reduced at 50-60°C. Pressure recovery, add isopropyl ether (20ml) to the residual solid and heat to 60°C and stir, the solid dissolves and cool to 50°C, add 1g of activated carbon powder, reheat to 60°C and stir for 30 minutes, filter the insoluble matter while it is hot, and the filtrate is stirred Cooled to 15°C to 20°C and left to stand for 10 hours, the product was filtered and the filter cake was washed with cold isopropyl ether (5ml×2), dried in vacuo at 60°C for 5 hours to obtain a light yellow solid (7.4g), yield: 84.7 %,mp:138~139℃,ESI-MSm/z:402[M+H] + ,424[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

将N-(4-异丁氧基苄基)氨基甲酸笏甲酯(3g)与20%哌啶胺(15ml)在二甲基甲酰胺中(10ml)溶解,在室温搅拌3小时,用TLC检测原料剩余。反应完成后后脱除溶剂,加入二氯甲烷(10ml*2),水(5ml*2)洗,脱去溶剂得到油状氨基碱0.82g,收率52%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve N-(4-isobutoxybenzyl)methyl carbamate (3g) and 20% piperidinamine (15ml) in dimethylformamide (10ml), stir at room temperature for 3 hours, and use TLC Check raw material remaining. After the reaction was completed, the solvent was removed, dichloromethane (10ml*2) was added, washed with water (5ml*2), the solvent was removed to obtain 0.82g of oily amino base, the yield was 52%, ESI-MS m/z: 180[ M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(10g)油状液体溶解二氯甲烷(60ml)中,然后添加无水碳酸钾(12g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(15.7g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(25ml*2)洗涤,分层得到有机层用水(20ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(20g)粗品,加入甲醇(30ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(10ml*2)洗涤滤饼。于60℃真空干燥2小时,得到13.4g白色固体纯品,收率80%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (10g) deprotected in dichloromethane (60ml) at room temperature, then add anhydrous potassium carbonate (12g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (15.7 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, remove the inorganic salt by filtration, wash the filter cake with DCM (30ml*2), wash the filtrate with 10% HCl (25ml*2), separate the layers to obtain the organic layer, wash with water (20ml*2), after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (20 g), which was added with methanol (30 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (10ml*2). Vacuum dried at 60°C for 2 hours to obtain 13.4g white solid pure product, yield 80%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(21g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(13g)溶解在乙醇(80ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。N-(4-isobutoxybenzyl)phenyl carbamate (21g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (13g) were dissolved in ethanol ( 80ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(4.39g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(120ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(22g),收率88%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1H NMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (4.39g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (120ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (22g), yield 88%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 H NMR (400MHz, CDCl 3 )δ7.25 (dd, J=8.3, 5.7Hz, 2H, Ar-H), 7.11 (dt, J=8.7 and 4.5Hz, 4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例8,以三甲基硅乙氧羰基作保护基团Example 8, using trimethylsilylethoxycarbonyl as a protecting group

1)N-(4-羟基苄基)氨基甲酸-(2,2,2-三甲基硅烷基)乙酯1) N-(4-hydroxybenzyl)carbamate-(2,2,2-trimethylsilyl)ethyl ester

于室温将4-羟基苄胺(15g)和碳酸氢钠(25g)加入到二氯甲烷(90ml)中搅拌,在0℃到20℃用1小时将2,2,2-三甲基硅乙氧甲酰氯(38.6g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌12小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用二氯甲烷(45ml×2)洗涤滤饼。滤液用5%稀盐酸(15ml×2)洗涤,再用水(70ml×2)洗涤,分层后弃去水层,有机层干燥。30℃到40℃减压回收溶剂,在40℃下真空干燥5小时,得到红色液体14.8g,收率:61.5%,ESI-MS m/z:268[M+H]+,290[M+Na]+ 4-Hydroxybenzylamine (15g) and sodium bicarbonate (25g) were added to dichloromethane (90ml) at room temperature and stirred, and 2,2,2-trimethylsilyl ethyl Oxoformyl chloride (38.6 g) was added dropwise to the suspension. After the addition was complete, the mixture was stirred at 20°C to 25°C for 12 hours, starting material remaining by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with dichloromethane (45ml x 2). The filtrate was washed with 5% dilute hydrochloric acid (15ml×2), and then washed with water (70ml×2). After separating the layers, the aqueous layer was discarded, and the organic layer was dried. The solvent was recovered under reduced pressure at 30°C to 40°C, and dried under vacuum at 40°C for 5 hours to obtain 14.8g of red liquid, yield: 61.5%, ESI-MS m/z: 268[M+H] + , 290[M+ Na] +

2)N-(4-异丁氧基苄基)氨基甲酸-(2,2,2-三甲基硅烷基)乙酯2) N-(4-isobutoxybenzyl)carbamate-(2,2,2-trimethylsilyl)ethyl ester

于室温将N-(4-羟基苄基)氨基甲酸-(2,2,2-三甲基硅烷基)乙酯(11g)溶解在二甲基甲酰胺(66ml)中,然后在<30℃分批加入无水碳酸钾(13g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(11g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用二氯甲烷(150ml)稀释,用5%NaOH(30ml×2)洗涤二氯甲烷溶液,然后水(50ml×2)洗涤,水层弃去,二氯甲烷溶液在50℃下减压回收,在40℃真空干燥5小时,得到棕色油状液体(7.1g),收率:83.3%,ESI-MS m/z:324[M+H]+,346[M+Na]+ Dissolve N-(4-hydroxybenzyl)carbamate-(2,2,2-trimethylsilyl)ethyl ester (11g) in dimethylformamide (66ml) at room temperature, and then Anhydrous potassium carbonate (13 g) was added portionwise and the suspension was heated to 78°C to 82°C. Isobutane bromide (11 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (50ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with dichloromethane (150ml), the dichloromethane solution was washed with 5% NaOH (30ml×2), then water (50ml×2), the aqueous layer was discarded, and the dichloromethane solution was decompressed at 50°C Recovered and dried under vacuum at 40°C for 5 hours to obtain a brown oily liquid (7.1g), yield: 83.3%, ESI-MS m/z: 324[M+H] + , 346[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

将N-(4-异丁氧基苄基)氨基甲酸-(2,2,2-三甲基硅烷基)乙酯(5g)与四丁基氟化铵(7.3g)溶解在四氢呋喃(50ml)中,该溶液在室温下搅拌12小时,用TLC检测反应原料剩余。反应完成后,减压回收溶剂,用二氯甲烷(15ml*2)萃取残余液体,水(50ml*2)洗分层,弃去水层,脱去溶剂,得到油状氨基碱2.1g,收率68%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve N-(4-isobutoxybenzyl)carbamate-(2,2,2-trimethylsilyl)ethyl ester (5g) and tetrabutylammonium fluoride (7.3g) in tetrahydrofuran (50ml ), the solution was stirred at room temperature for 12 hours, and the remainder of the reaction raw material was detected by TLC. After the reaction was completed, the solvent was recovered under reduced pressure, the residual liquid was extracted with dichloromethane (15ml*2), the layers were washed with water (50ml*2), the water layer was discarded, and the solvent was removed to obtain 2.1g of oily amino base, the yield 68%, ESI-MS m/z: 180[M+H] + ,202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(25g)油状液体溶解二氯甲烷(150ml)中,然后添加无水碳酸钾(33g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(41.4g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(45g)粗品,加入甲醇(60ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到33g白色固体纯品,收率79%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve 4-isobutoxybenzylamine (25g) oily liquid which has been deprotected in dichloromethane (150ml) at room temperature, then add anhydrous potassium carbonate (33g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (41.4 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (100ml*2), the layers were separated to obtain an organic layer, washed with water (100ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (45 g), which was added with methanol (60 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 33g white solid pure product, yield 79%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(22.6g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(14g)溶解在乙醇(100ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (22.6g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (14g) in ethanol at room temperature (100ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(5.2g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(120ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(24.8g),收率92%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (5.2 g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (120ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (24.8g), yield 92%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例9,以对甲苯磺酰基作保护基团Embodiment 9, using p-toluenesulfonyl as protecting group

1)N-(4-羟基苄基)-N-(4-甲基苯基)磺酰胺1) N-(4-hydroxybenzyl)-N-(4-methylphenyl)sulfonamide

于室温将4-羟基苄胺(10g)和碳酸氢钠(25g)加入到四氢呋喃(90ml)中搅拌,在0℃到20℃用1小时将对甲苯磺酰氯(38.6g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌10小时,再升温至50℃搅拌2小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用四氢呋喃(40ml×2)洗涤滤饼。滤液用5%稀盐酸(10ml×2)洗涤,再用水(40ml×2)洗涤分层,有机层干燥。60℃到80℃减压回收溶剂,在60℃下真空干燥3h,得到黄色油状液体10g,收率:68.9%,ESI-MS m/z:278[M+H]+,300[M+Na]+ 4-Hydroxybenzylamine (10g) and sodium bicarbonate (25g) were added to tetrahydrofuran (90ml) at room temperature and stirred, and p-toluenesulfonyl chloride (38.6g) was added dropwise to the suspension at 0°C to 20°C for 1 hour middle. After the addition was complete, the mixture was stirred at 20°C to 25°C for 10 hours, then warmed up to 50°C and stirred for 2 hours, and the remaining starting material was detected by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with tetrahydrofuran (40ml×2). The filtrate was washed with 5% dilute hydrochloric acid (10ml×2), and the layers were washed with water (40ml×2), and the organic layer was dried. The solvent was recovered under reduced pressure at 60°C to 80°C, and dried in vacuum at 60°C for 3 hours to obtain 10 g of yellow oily liquid, yield: 68.9%, ESI-MS m/z: 278[M+H] + , 300[M+Na ] +

2)N-(4-异丁氧基苄基)-N-(4-甲基苯基)磺酰胺2) N-(4-isobutoxybenzyl)-N-(4-methylphenyl)sulfonamide

于室温将N-(4-羟基苄基)-N-(4-甲基苯基)磺酰胺液体(13g)溶解在二甲基甲酰胺(65ml)中,然后在<30℃分批加入无水碳酸钾(16g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(14g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用二氯甲烷(100ml)稀释,加入5%NaOH(50ml×2)洗涤,再用水(100ml×2)洗涤分层,水层弃去,溶剂在50-60℃下减压回收,在60℃真空干燥5小时,得到淡棕色油状液体(9.4g),收率:80.1%,ESI-MS m/z:334[M+H]+,356[M+Na]+ N-(4-hydroxybenzyl)-N-(4-methylphenyl)sulfonamide liquid (13g) was dissolved in dimethylformamide (65ml) at room temperature, and then added in portions at <30°C without Potassium carbonate water (16 g) and the suspension heated to 78°C to 82°C. Isobutane bromide (14 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (50ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with dichloromethane (100ml), washed with 5% NaOH (50ml×2), washed with water (100ml×2), and the water layer was discarded. The solvent was recovered under reduced pressure at 50-60°C, and the Vacuum drying at 60°C for 5 hours gave light brown oily liquid (9.4g), yield: 80.1%, ESI-MS m/z: 334[M+H] + , 356[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于-78℃下将N-(4-异丁氧基苄基)-N-(4-甲基苯基)磺酰胺(0.25g)加入到萘酚钠(15ml,奈酚2g,钠1g)的四氢呋喃(20ml)溶液中,并在该温度氮气保护下搅拌10小时。反应完成后,加入水(5ml)终止反应,减压除去溶剂,加入水(5ml),并用乙酸乙酯(10ml*2)萃取,然后用饱和食盐水(10ml*2)洗,干燥后减压回收溶剂,得到油状氨基碱0.09g,收率:59%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Add N-(4-isobutoxybenzyl)-N-(4-methylphenyl)sulfonamide (0.25g) to sodium naphthol (15ml, naphthol 2g, sodium 1g) at -78°C THF (20ml) and stirred at this temperature for 10 hours under nitrogen protection. After the reaction is complete, add water (5ml) to terminate the reaction, remove the solvent under reduced pressure, add water (5ml), and extract with ethyl acetate (10ml*2), then wash with saturated brine (10ml*2), dry and reduce pressure The solvent was recovered to obtain 0.09g of oily amino base, yield: 59%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(21g)油状液体溶解二氯甲烷(120ml)中,然后添加无水碳酸钾(29g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(36.6g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(45g)粗品,加入甲醇(75ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到28.4g白色固体纯品,收率81%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (21g) deprotected in dichloromethane (120ml) at room temperature, then add anhydrous potassium carbonate (29g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (36.6 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (100ml*2), the layers were separated to obtain an organic layer, washed with water (100ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (45g), which was added with methanol (75ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 28.4g white solid pure product, yield 81%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(25.9g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(16g)溶解在乙醇(120ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (25.9g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (16g) in ethanol at room temperature (120ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(6.49g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(130ml) 加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(26.2g),收率85%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solids (6.49 g) were added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (130ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C for 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (26.2g), yield 85%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例10,以三苯甲基作保护基团Embodiment 10, using trityl as protecting group

1)N-(4-羟基苄基)-三苯甲基胺1) N-(4-hydroxybenzyl)-tritylamine

于室温将4-羟基苄胺(12g)和三乙胺(22g)加入到氯仿(60ml)中搅拌,在0℃到20℃用1小时将三苯基氯甲烷(57.1g)的氯仿溶液滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌10小时,再升温至40℃搅拌2小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去三乙胺盐。用氯仿(30ml×2)洗涤滤饼。用水(50ml×2)洗涤分层,有机层干燥。60℃到80℃减压回收溶剂,固体用正己烷(50ml*2)洗涤,过滤淡黄色粉末,在60℃下真空干燥3h,得到10.5g。收率:66.8%,mp:182~184℃,ESI-MS m/z:366[M+H]+,388[M+Na]+ 4-Hydroxybenzylamine (12g) and triethylamine (22g) were added to chloroform (60ml) and stirred at room temperature, and a chloroform solution of triphenylchloromethane (57.1g) was added dropwise at 0°C to 20°C for 1 hour added to the suspension. After the addition was complete, the mixture was stirred at 20°C to 25°C for 10 hours, then warmed up to 40°C and stirred for 2 hours, and the remaining starting material was detected by TLC. After the reaction was completed, suction filtration was performed to remove triethylamine salt. The filter cake was washed with chloroform (30ml x 2). The layers were washed with water (50ml×2), and the organic layer was dried. The solvent was recovered under reduced pressure at 60°C to 80°C, the solid was washed with n-hexane (50ml*2), the light yellow powder was filtered, and vacuum-dried at 60°C for 3h to obtain 10.5g. Yield: 66.8%, mp: 182~184℃, ESI-MS m/z: 366[M+H] + , 388[M+Na] +

2)N-(4-异丁氧基苄基)-三苯甲基胺2) N-(4-isobutoxybenzyl)-tritylamine

于室温将N-(4-羟基苄基)-三苯甲基胺(15g)溶解在二甲基甲酰胺(120ml)中,然后在<30℃分批加入无水碳酸钾(14g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(14g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(50ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用乙醇(50ml)稀释,然后倾入水(200ml)中,过滤析出的固体,加入5%NaOH(50ml×2)洗涤,再用水(80ml×2)洗涤,固体在60℃真空干燥5小时,得到白色粉末(8.1g),收率:78.3%,mp:141~143℃,ESI-MS m/z:422[M+H]+,444[M+Na]+ N-(4-hydroxybenzyl)-tritylamine (15 g) was dissolved in dimethylformamide (120 ml) at room temperature, then anhydrous potassium carbonate (14 g) was added in portions at <30° C., and The suspension was heated to 78°C to 82°C. Isobutane bromide (14 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (50ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with ethanol (50ml), then poured into water (200ml), filtered the precipitated solid, added 5% NaOH (50ml×2) to wash, and then washed with water (80ml×2), and the solid was vacuum-dried at 60°C for 5 hours , to obtain white powder (8.1g), yield: 78.3%, mp: 141~143℃, ESI-MS m/z: 422[M+H] + , 444[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于室温将N-(4-异丁氧基苄基)-三苯甲基胺8g溶解在四氢呋喃(50ml)中,然后在0-20℃,将冰醋酸(40ml)滴加至溶液中,滴加完成后加热至40℃搅拌4小时,用TLC检测原料剩余。反应完成后,在0-25℃下将溶液PH调至碱性,并用水(25ml*2)洗分层,30℃减压浓缩溶剂,得到油状氨基碱3.1g,收率79%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve 8 g of N-(4-isobutoxybenzyl)-tritylamine in tetrahydrofuran (50 ml) at room temperature, then add glacial acetic acid (40 ml) dropwise to the solution at 0-20°C, dropwise After the addition was complete, it was heated to 40° C. and stirred for 4 hours, and the remaining raw material was detected by TLC. After the reaction was completed, the pH of the solution was adjusted to alkaline at 0-25°C, and the layers were washed with water (25ml*2), and the solvent was concentrated under reduced pressure at 30°C to obtain 3.1g of oily amino base, with a yield of 79%, ESI- MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(14g)油状液体溶解二氯甲烷(120ml)中,然后添加无水碳酸钾(22g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(14.6g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(25g)粗品,加入甲醇(40ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到19.4g白色固体纯品,收率83%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (14g) deprotected in dichloromethane (120ml) at room temperature, then add anhydrous potassium carbonate (22g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (14.6 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (100ml*2), the layers were separated to obtain an organic layer, washed with water (100ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (25 g), which was added with methanol (40 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 19.4g white solid pure product, yield 83%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(15.8g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(9g)溶解在乙醇(70ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (15.8g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (9g) in ethanol at room temperature (70ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(3.95g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(150ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(14.5g),收率84.2%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (3.95 g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (14.5g), yield 84.2%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例11,以2,4-二甲氧基苄基作保护基团Example 11, using 2,4-dimethoxybenzyl as a protecting group

1)N-(4-羟基苄基)-N-(2,4-二甲氧基)苄胺1) N-(4-hydroxybenzyl)-N-(2,4-dimethoxy)benzylamine

室温下将4-羟基苄胺(15g)和2,4-二甲氧基苯甲醛(10g)溶解在二氯甲烷(50ml)中,于0-15℃将三乙酰基硼氢化钠(17g)分批加入该悬浮液。添加结束后,在20-25℃下搅拌12小时,用TLC检测剩余原料。反应结束后,将不溶物过滤并用二氯甲烷(20ml*2)洗涤滤饼,在0-20℃下加入氢氧化钠(3g-5g)调PH10至12,然后水(100ml*2)洗分层,有机层干燥后40℃减压除去溶剂,60℃真空干燥2小时,得到棕色油状17g,收率:77.5%,ESI-MS m/z:244[M+H]+,266[M+Na]+ 4-Hydroxybenzylamine (15g) and 2,4-dimethoxybenzaldehyde (10g) were dissolved in dichloromethane (50ml) at room temperature, and sodium triacetylborohydride (17g) was dissolved at 0-15°C The suspension was added in portions. After the addition was complete, it was stirred at 20-25°C for 12 hours, and the remaining starting material was checked by TLC. After the reaction, filter the insoluble matter and wash the filter cake with dichloromethane (20ml*2), add sodium hydroxide (3g-5g) at 0-20°C to adjust the pH from 10 to 12, then wash with water (100ml*2) After the organic layer was dried, the solvent was removed under reduced pressure at 40°C, and the solvent was dried under vacuum at 60°C for 2 hours to obtain 17g of brown oil, yield: 77.5%, ESI-MS m/z: 244[M+H] + , 266[M+ Na] +

2)N-(4-异丁氧基苄基)-N-(2,4-二甲氧基)苄胺2) N-(4-isobutoxybenzyl)-N-(2,4-dimethoxy)benzylamine

于室温下将N-(4-羟基苄基)-N-(2,4-二甲氧基)苄胺(12g)溶解在二甲基甲酰胺(90ml)中,然后在<30℃分批加入无水碳酸钾(18g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(17g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(30ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用二氯甲烷(100ml)稀释,加入5%NaOH(50ml×2)洗涤,再用水(50ml×2)洗涤,除去溶剂并在60℃真空干燥5小时,得到黑色油状液体(9.3g),收率:75.1%,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve N-(4-hydroxybenzyl)-N-(2,4-dimethoxy)benzylamine (12 g) in dimethylformamide (90 ml) at room temperature, then batchwise at <30°C Anhydrous potassium carbonate (18 g) was added and the suspension was heated to 78°C to 82°C. Isobutane bromide (17 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (30ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with dichloromethane (100ml), washed with 5% NaOH (50ml x 2), washed with water (50ml x 2), solvent removed and vacuum dried at 60°C for 5 hours to give a black oily liquid (9.3g) , Yield: 75.1%, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于室温将N-(4-异丁氧基苄基)-N-(2,4-二甲氧基)苄胺3g溶解在四氢呋喃(30ml)中,然后在0-20℃,将盐酸(6ml)滴加至溶液中,滴加完成后加热至回流温度搅拌8小时,用TLC检测原料剩余。反应完成后,减压脱去溶剂,加入二氯甲烷(10ml),在0-25℃下将溶液PH调至碱性,并用水(20ml*2)洗分层,30℃减压浓缩溶剂,得到油状氨基碱1.4g,收率68%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve 3 g of N-(4-isobutoxybenzyl)-N-(2,4-dimethoxy)benzylamine in tetrahydrofuran (30ml) at room temperature, and then dissolve hydrochloric acid (6ml ) was added dropwise to the solution, heated to reflux temperature and stirred for 8 hours after the dropwise addition was completed, and the remaining raw materials were detected by TLC. After the reaction was completed, the solvent was removed under reduced pressure, dichloromethane (10ml) was added, the pH of the solution was adjusted to alkaline at 0-25°C, the layers were washed with water (20ml*2), and the solvent was concentrated under reduced pressure at 30°C. 1.4 g of oily amino base was obtained, the yield was 68%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(18g)油状液体溶解二氯甲烷(140ml)中,然后添加无水碳酸钾(35g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(23.5g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(30g)粗品,加入甲醇(50ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到25.6g白色固体纯品,收率85%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (18g) deprotected in dichloromethane (140ml) at room temperature, then add anhydrous potassium carbonate (35g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (23.5 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (100ml*2), the layers were separated to obtain an organic layer, washed with water (100ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (30 g), which was added with methanol (50 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 25.6g of pure white solid, yield 85%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(17.5g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(10g)溶解在乙醇(80ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenylcarbamate (17.5g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (10g) in ethanol at room temperature (80ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(4.05g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(150ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(15.6g),收率84%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (4.05g) was added to the ethanol solution prepared in Example 5 (yield 100%, calculated as piperidinamine) at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (15.6g), yield 84%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例12,以4-甲氧基苄基作保护基团Example 12, using 4-methoxybenzyl as protecting group

1)N-(4-羟基苄基)-N-(4-甲氧基)苄胺1) N-(4-hydroxybenzyl)-N-(4-methoxy)benzylamine

室温(25℃,下同)下将4-羟基苄胺(18g)和4-甲氧基苯甲醛(20.5g)溶解在二氯甲烷(50ml)中,于0-15℃将三乙酰基硼氢化钠(31g)分批加入该悬浮液。添加结束后,在20-25℃下搅拌12小时,用TLC检测剩余原料。反应结束后,将不溶物过滤并用二氯甲烷(20ml*2)洗涤滤饼,滤液用20%HCl水溶液(50ml*2)调PH至2到3,在0-20℃下加入氢氧化钠(3g-5g)调PH10至12,然后水(100ml*2)洗分层,有机层干燥后40℃减压除去溶剂,60℃真空干燥2小时,得到明黄色固体27.4g,收率:75.7%,mp:179~179.5℃,ESI-MS m/z:274[M+H]+,296[M+Na]+ Dissolve 4-hydroxybenzylamine (18g) and 4-methoxybenzaldehyde (20.5g) in dichloromethane (50ml) at room temperature (25°C, the same below), and dissolve triacetylboron at 0-15°C Sodium hydride (31 g) was added to the suspension in portions. After the addition was complete, it was stirred at 20-25°C for 12 hours, and the remaining starting material was checked by TLC. After the reaction, the insoluble matter was filtered and the filter cake was washed with dichloromethane (20ml*2), the filtrate was adjusted to PH to 2 to 3 with 20% HCl aqueous solution (50ml*2), and sodium hydroxide ( 3g-5g) adjust the pH from 10 to 12, then wash the layers with water (100ml*2), remove the solvent under reduced pressure at 40°C after the organic layer is dried, and dry in vacuum at 60°C for 2 hours to obtain 27.4g of bright yellow solid, yield: 75.7% ,mp:179~179.5℃,ESI-MS m/z:274[M+H] + ,296[M+Na] +

2)N-(4-异丁氧基苄基)-N-(4-甲氧基)苄胺2) N-(4-isobutoxybenzyl)-N-(4-methoxy)benzylamine

于室温下将N-(4-羟基苄基)-N-(4-二甲氧基)苄胺(15g)溶解在无水乙醇(135ml)中,然后在<30℃分批加入无水碳酸钾(21g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(21g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌24小时,通过TLC检测剩余原料。反应完成后,将悬浮液冷却到20℃到30℃,进行抽滤以除去过量钾盐,用二氯甲烷(30ml×2)洗涤滤饼。减压回收二甲基甲酰胺。残余物用乙醇(30ml)稀释,然后倾入水(150ml)中,过滤析出的固体,固体加入5%NaOH(50ml×2)洗涤,再用水(50ml×2)洗涤,将固体抽滤并在60℃真空干燥5小时,得到深黄色粉末(6.9g),收率:50.1%,mp:122~124℃,ESI-MS m/z:330[M+H]+,352[M+Na]+ Dissolve N-(4-hydroxybenzyl)-N-(4-dimethoxy)benzylamine (15g) in absolute ethanol (135ml) at room temperature, then add anhydrous carbonic acid in batches at <30°C Potassium (21 g), and the suspension was heated to 78°C to 82°C. Isobutane bromide (21 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 24 hours and the remaining starting material was checked by TLC. After the reaction was completed, the suspension was cooled to 20°C to 30°C, suction filtered to remove excess potassium salt, and the filter cake was washed with dichloromethane (30ml×2). Dimethylformamide was recovered under reduced pressure. The residue was diluted with ethanol (30ml), then poured into water (150ml), and the precipitated solid was filtered, washed with 5% NaOH (50ml×2) and then washed with water (50ml×2), the solid was suction-filtered and dried at 60 Vacuum drying at ℃ for 5 hours to obtain dark yellow powder (6.9g), yield: 50.1%, mp: 122~124℃, ESI-MS m/z: 330[M+H] + , 352[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

于室温将N-(4-异丁氧基苄基)-N-(4-甲氧基)苄胺6g溶解在二氯甲烷(60ml)中,然后在-25-0℃,将三氟乙酸(48ml)滴加至溶液中,滴加完成后转至室温搅拌5小时,用TLC检测原料剩余。反应完成后,在0-25℃下将溶液PH调至碱性,并用水(20ml*2)洗分层,30℃减压浓缩,得到油状氨基碱3.4g,收率77%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Dissolve 6 g of N-(4-isobutoxybenzyl)-N-(4-methoxy)benzylamine in dichloromethane (60ml) at room temperature, and then dissolve trifluoroacetic acid at -25-0°C (48ml) was added dropwise into the solution, and after the dropwise addition was completed, it was turned to room temperature and stirred for 5 hours, and the remaining raw materials were detected by TLC. After the reaction was completed, adjust the pH of the solution to alkaline at 0-25°C, wash the layers with water (20ml*2), and concentrate under reduced pressure at 30°C to obtain 3.4g of oily amino base with a yield of 77%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(15g)油状液体溶解二氯甲烷(120ml)中,然后添加无水碳酸钾(34g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(23.5g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(30g)粗品,加入甲醇(50ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到21.3g白色固体纯品,收率85%,mp:98.2~99.5℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (15g) deprotected in dichloromethane (120ml) at room temperature, then add anhydrous potassium carbonate (34g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (23.5 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (100ml*2), the layers were separated to obtain an organic layer, washed with water (100ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (30 g), which was added with methanol (50 ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 21.3g of pure white solid, yield 85%, mp: 98.2~99.5°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(10g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(7g)溶解在乙醇(50ml)中,加热至回流并搅拌8小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。N-(4-isobutoxybenzyl)phenyl carbamate (10g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (7g) were dissolved in ethanol ( 50ml), heated to reflux and stirred for 8 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(2.25g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(80ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(13g),收率82.8%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1H NMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5Hz,4H,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5Hz,2H,CH2),2.98(d,J=11.1Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6Hz,2H,CH2),1.73(q,J=12.3Hz,2H,CH2),1.51(d,J=11.4Hz,2H,CH2),0.97(d,J=6.7Hz,6H,CH3);13C NMR(400MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4.Tartaric acid solid (2.25g) was added to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stirred at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (80ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (13g), yield 82.8%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 H NMR (400MHz, CDCl 3 )δ7.25 (dd, J=8.3, 5.7Hz, 2H, Ar-H), 7.11 (dt, J=8.7 and 4.5Hz, 4H ,Ar-H),6.83(d,J=8.6Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5Hz,2H,CH 2 ),2.98(d,J=11.1Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6Hz,2H,CH 2 ),1.73(q,J=12.3Hz,2H,CH 2 ),1.51(d,J=11.4Hz, 2H, CH 2 ), 0.97 (d, J=6.7Hz, 6H, CH 3 ); 13 C NMR (400MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35, 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53; IR (CM -1 ): 3425.1,2930.3,1647.6,1383.9,86.9,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,856.3,56.3,856.3,856.3,856.3,8.9,8.9. ,732.4.

实施例13,以苄基作保护基团Example 13, using benzyl as protecting group

1)N-(4-羟基苄基)苄胺1) N-(4-hydroxybenzyl)benzylamine

于室温将4-羟基苄胺(10g)和碳酸氢钠(20g)加入到二氯甲烷(100ml)中搅拌,在0℃到20℃用1小时将溴化苄(34.8g)滴加到悬浮液中。添加结束后,将该混合物在20℃到25℃搅拌5小时,用TLC检测起始原料剩余。反应完成后,进行抽滤以除去过量钠盐。用氯甲烷(50ml×2)洗涤滤饼。滤液用5%稀盐酸(20ml×2)洗涤,再用水(70ml×2)洗涤分层,有机层干燥。60℃减压回收溶剂,残留物加入甲苯(100ml)并加热至80℃搅拌溶解,降温至20℃放置5小时,在60℃下真空干燥3h,得到白色固体9.1g。收率:73.3%,mp:99~100℃,ESI-MSm/z:214[M+H]+,236[M+Na]+ 4-Hydroxybenzylamine (10g) and sodium bicarbonate (20g) were added to dichloromethane (100ml) at room temperature and stirred, and benzyl bromide (34.8g) was added dropwise to the suspension at 0°C to 20°C for 1 hour in the liquid. After the addition was complete, the mixture was stirred at 20°C to 25°C for 5 hours, and the remaining starting material was checked by TLC. After the reaction was completed, suction filtration was performed to remove excess sodium salt. The filter cake was washed with methyl chloride (50ml x 2). The filtrate was washed with 5% dilute hydrochloric acid (20ml×2), and the layers were washed with water (70ml×2), and the organic layer was dried. The solvent was recovered under reduced pressure at 60°C, the residue was added toluene (100ml) and heated to 80°C with stirring to dissolve, cooled to 20°C for 5 hours, and vacuum dried at 60°C for 3h to obtain 9.1g of white solid. Yield: 73.3%, mp: 99~100℃, ESI-MSm/z: 214[M+H] + , 236[M+Na] +

2)N-(4-异丁氧基苄基)苄胺2) N-(4-isobutoxybenzyl)benzylamine

于室温将N-(4-羟基苄基)苄胺(15g)溶解在二甲基甲酰胺(150ml)中,然后在<30℃分批加入二氮杂二环(DBU,29g),并将该悬浮液加热到78℃到82℃。于78℃到82℃用2小时将溴代异丁烷(29g)滴加到悬浮液中。添加结束后,将该混合物在78℃-82℃搅拌36小时,通过TLC检测剩余原料。反应完成后,减压回收二甲基甲酰胺。残余物用二氯甲烷(30ml)稀释,分别用5%稀盐酸(100ml×2)洗涤,水(30ml×2)洗涤,5%NaOH(50ml×2)洗涤二氯甲烷溶液,再用水(30ml×2)洗涤分层,水层弃去,溶剂在50-60℃下减压回收,残余固体加入乙醇(40ml)加热至60℃搅拌,固体溶解后冷却至室温并静置10小时,将晶体过滤并用冷异丙醚(10ml×2)洗涤滤饼,60℃真空干燥5小时,得到浅黄色粉末(12.5g),收率:70.8%,mp:71~73℃,ESI-MS m/z:280[M+H]+,302[M+Na]+ Dissolve N-(4-hydroxybenzyl)benzylamine (15g) in dimethylformamide (150ml) at room temperature, then add diazabicyclo (DBU, 29g) in portions at <30°C, and The suspension was heated to 78°C to 82°C. Isobutane bromide (29 g) was added dropwise to the suspension at 78°C to 82°C over 2 hours. After the addition was complete, the mixture was stirred at 78°C-82°C for 36 hours and the remaining starting material was checked by TLC. After the reaction was completed, dimethylformamide was recovered under reduced pressure. The residue was diluted with dichloromethane (30ml), washed with 5% dilute hydrochloric acid (100ml×2), washed with water (30ml×2), washed with 5% NaOH (50ml×2) in dichloromethane solution, and then washed with water (30ml ×2) Wash and separate layers, discard the water layer, recover the solvent under reduced pressure at 50-60°C, add ethanol (40ml) to the residual solid and heat to 60°C and stir, cool to room temperature after the solid dissolves and let stand for 10 hours, the crystal Filter and wash the filter cake with cold isopropyl ether (10ml×2), and vacuum-dry at 60°C for 5 hours to obtain light yellow powder (12.5g), yield: 70.8%, mp: 71~73°C, ESI-MS m/z :280[M+H] + ,302[M+Na] +

3)4-异丁氧基苄胺3) 4-isobutoxybenzylamine

与室温将N-(4-异丁氧基苄基)苄胺8g与5%Pd-C(0.5g)加入乙醇(60ml)中搅拌,在室温下通入氢气并搅拌5小时,用TLC检测原料剩余。反应完成后过滤回收钯碳,将溶剂减压回收,得到游离碱5.1g,收率78%,ESI-MS m/z:180[M+H]+,202[M+Na]+ Add 8 g of N-(4-isobutoxybenzyl) benzylamine and 5% Pd-C (0.5 g) into ethanol (60 ml) and stir at room temperature, and stir with hydrogen gas at room temperature for 5 hours, and detect with TLC Raw material remaining. After the reaction was completed, palladium carbon was recovered by filtration, and the solvent was recovered under reduced pressure to obtain 5.1 g of free base, with a yield of 78%, ESI-MS m/z: 180[M+H] + , 202[M+Na] +

4)N-(4-异丁氧基苄基)氨基甲酸苯酯4) Phenyl N-(4-isobutoxybenzyl)carbamate

于室温将脱去保护基的4-异丁氧基苄胺(30g)油状液体溶解二氯甲烷(120ml)中,然后添加无水碳酸钾(34g),将悬浮液冷却至0℃到10℃,并在0℃到10℃用1小时将氯甲酸苯酯(31g)滴加到该悬浮液中。添加结束后,将该混合物移至20℃到25℃下搅拌1小时,通过TLC检测原料剩余。反应结束后,过滤除掉无机盐,以DCM(30ml*2)洗涤滤饼,滤液用10%HCl(100ml*2)洗涤,分层得到有机层用水(100ml*2)洗涤,经干燥后,30℃减压回收溶剂,得到白色固体(45g)粗品,加入甲醇(180ml)加热至回流约0.5小时至固体全部溶解。用约1小时将该溶液冷却至10℃并静置5小时。将产物过滤,并以冷甲醇(20ml*2)洗涤滤饼。于60℃真空干燥2小时,得到38g白色固体纯品,收率76%,mp:98.5~99.2℃,ESI-MS m/z:300[M+H]+,322[M+Na]+.Dissolve the oily liquid of 4-isobutoxybenzylamine (30g) deprotected in dichloromethane (120ml) at room temperature, then add anhydrous potassium carbonate (34g), and cool the suspension to 0°C to 10°C , and phenyl chloroformate (31 g) was added dropwise to the suspension at 0°C to 10°C over 1 hour. After the addition was complete, the mixture was moved to 20°C to 25°C and stirred for 1 hour, starting material remained by TLC. After the reaction, the inorganic salts were removed by filtration, the filter cake was washed with DCM (30ml*2), the filtrate was washed with 10% HCl (100ml*2), the layers were separated to obtain an organic layer, washed with water (100ml*2), and after drying, The solvent was recovered under reduced pressure at 30°C to obtain a crude white solid (45g), which was added to methanol (180ml) and heated to reflux for about 0.5 hours until the solid was completely dissolved. The solution was cooled to 10°C over about 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold methanol (20ml*2). Vacuum dried at 60°C for 2 hours to obtain 38g white solid pure product, yield 76%, mp: 98.5~99.2°C, ESI-MS m/z: 300[M+H] + , 322[M+Na] + .

5)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲5) N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N’-(4-isobutoxybenzyl)urea

于室温将N-(4-异丁氧基苄基)氨基甲酸苯酯(20g)与N-(4-氟苄基)-1-甲基-4-哌啶胺(13.5g)溶解在乙醇(100ml)中,加热至回流并搅拌3小时,用TLC检测剩余原料N-(4-氟苄基)-1-甲基-4-哌啶胺。反应结束后,即得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的醇溶液。Dissolve N-(4-isobutoxybenzyl)phenyl carbamate (20g) and N-(4-fluorobenzyl)-1-methyl-4-piperidinamine (13.5g) in ethanol at room temperature (100ml), heated to reflux and stirred for 3 hours, and the remaining raw material N-(4-fluorobenzyl)-1-methyl-4-piperidinamine was detected by TLC. After the reaction, the alcohol solution of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea is obtained.

6)N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的制备6) Preparation of tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea

在40℃到45℃用30分钟将酒石酸固体(4.5g)添加到实施例5中制备的乙醇溶液(收率100%,以哌啶胺计)中,在该温下搅拌2小时,将该溶液冷却至30℃到35℃,产物在约34℃结晶,在此温度下将该悬浮液搅拌30分钟,然后用1小时将其冷却至0℃并静置5小时。将该产物过滤,并以冷乙醇(20ml*2)洗涤滤饼。得到粗产品、湿品用无水乙醇(150ml)加热至回流并搅拌2小时,然后用1小时将溶液冷却至25℃到30℃,在此温度静置3小时。过滤该产物,并以冷乙醇(20ml*2)洗涤滤饼。在45℃真空干燥8小时,得到白色固体纯品(27.8g),收率84.8%,mp:135.5-137.5℃(文献133-135℃),ESI-MS m/z:428[M+H]+,450[M+Na]+1HNMR(400MHz,CDCl3)δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5 Hz,4H,Ar-H),6.83(d,J=8.6 Hz,2H,Ar-H),4.42(s,2H,CH2),4.19(d,J=5.5 Hz,2H,CH2),4.02(s,1H,CH),3.70(d,J=6.5 Hz,2H,CH2),2.98(d,J=11.1 Hz,2H,CH2),2.56–2.46(m,1H,NH),2.41–2.29(m,4H,CH2),1.99(dp,J=13.3,6.6 Hz,2H,CH2),1.73(q,J=12.3 Hz,2H,CH2),1.51(d,J=11.4 Hz,2H,CH2),0.97(d,J=6.7 Hz,6H,CH3);13C NMR(400 MHz,CDCl3)δ174.99,162.58,160.18,157.95,137.27,133.44,128.86,128.78,128.63,115.35,115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53;IR(cm-1):3425.1,2930.3,1693.3,1647.6,1383.9,1263.9,1074.3,856.6,834.2,780.1,732.4。Add tartaric acid solids (4.5 g) to the ethanol solution (yield 100%, calculated as piperidinamine) prepared in Example 5 at 40°C to 45°C for 30 minutes, stir at this temperature for 2 hours, and the The solution was cooled to 30°C to 35°C, the product crystallized at about 34°C, the suspension was stirred at this temperature for 30 minutes, then cooled to 0°C over 1 hour and allowed to stand for 5 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). The obtained crude product and the wet product were heated to reflux with absolute ethanol (150ml) and stirred for 2 hours, then the solution was cooled to 25°C to 30°C in 1 hour, and stood at this temperature for 3 hours. The product was filtered and the filter cake was washed with cold ethanol (20ml*2). Vacuum dried at 45°C for 8 hours to obtain pure white solid (27.8g), yield 84.8%, mp: 135.5-137.5°C (document 133-135°C), ESI-MS m/z: 428[M+H] + ,450[M+Na] + ; 1 HNMR(400MHz,CDCl 3 )δ7.25(dd,J=8.3,5.7Hz,2H,Ar-H),7.11(dt,J=8.7 and 4.5 Hz,4H ,Ar-H),6.83(d,J=8.6 Hz,2H,Ar-H),4.42(s,2H,CH 2 ),4.19(d,J=5.5 Hz,2H,CH 2 ),4.02(s ,1H,CH),3.70(d,J=6.5 Hz,2H,CH 2 ),2.98(d,J=11.1 Hz,2H,CH 2 ),2.56–2.46(m,1H,NH),2.41–2.29 (m,4H,CH 2 ),1.99(dp,J=13.3,6.6 Hz,2H,CH 2 ),1.73(q,J=12.3 Hz,2H,CH 2 ),1.51(d,J=11.4 Hz, 2H, CH 2 ), 0.97 (d, J=6.7 Hz, 6H, CH 3 ); 13 C NMR (400 MHz, CDCl 3 ) δ174.99, 162.58, 160.18, 157.95, 137.27, 133.44, 128.86, 128.78, 128.63, 115.35 , 115.14,114.54,74.23,72.37,54.39,51.69,49.07,44.57,43.58,28.97,28.18,19.53 ; 780.1, 732.4.

Claims (14)

1.一种N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法,其特征在于:以4-羟基苄胺为原料,经过氨基保护得N-保护基-4-羟基苄胺、再经烃化反应得到N-保护基-4-异丁氧基苄胺,然后经过脱保护反应制得4-异丁氧基苄胺,再与氯甲酸苯酯反应制得N-(4-异丁氧基苄基)氨基甲酸苯酯,最后通过与N-(4-氟苄基)-1-甲基-4-哌啶胺的氨解反应制得N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲,与酒石酸成盐,得到N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐,所述的保护基为苄氧羰基、笏甲氧羰基、叔丁氧羰基、三甲基硅乙氧羰基、甲氧羰基、乙氧羰基、甲酰基、乙酰基、对甲苯磺酰基、三苯甲基、2,4-二甲氧基苄基、4-甲氧基苄基或苄基。1. a synthetic method of the tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea, It is characterized in that: 4-hydroxybenzylamine is used as raw material, N-protecting group-4-hydroxybenzylamine is obtained through amino protection, and N-protecting group-4-isobutoxybenzylamine is obtained through alkylation reaction, and then through The deprotection reaction makes 4-isobutoxybenzylamine, then reacts with phenyl chloroformate to make N-(4-isobutoxybenzyl) phenyl carbamate, and finally reacts with N-(4-fluorobenzyl N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4- Isobutoxybenzyl) urea, salified with tartaric acid to give N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxy benzyl) urea tartrate, the protecting group is benzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, trimethylsilylethoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, formyl, acetyl, p-toluenesulfonyl, trityl, 2,4-dimethoxybenzyl, 4-methoxybenzyl or benzyl. 2.如权利要求1所述的一种N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法,其特征在于,包括如下步骤:2. A kind of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 The synthetic method of tartrate is characterized in that, comprises the steps: (1)制备式II所述的N-保护基-4-羟基苄胺:(1) N-protecting group-4-hydroxybenzylamine described in the preparation formula II: 以4-羟基苄胺为原料,经过保护试剂对氨基进行保护处理制得,Using 4-hydroxybenzylamine as raw material, it is prepared by protecting the amino group with a protecting reagent. 所述的保护试剂为氯甲酸苄酯、芴甲氧甲酰氯、二碳酸二叔丁酯、2,2,2-三甲基硅乙氧甲酰氯、氯甲酸乙酯、氯甲酸甲酯、甲乙酐、乙酸酐、对甲苯磺酰氯、三苯基氯甲烷、2,4-二甲氧基苯甲醛、2,4-二甲氧基苄基氯、4-甲氧基苯甲醛、4-甲氧基苄基氯、氯苄或溴苄;The protective reagents are benzyl chloroformate, fluorenylmethoxyformyl chloride, di-tert-butyl dicarbonate, 2,2,2-trimethylsilylethoxyformyl chloride, ethyl chloroformate, methyl chloroformate, methyl ethyl anhydride, acetic anhydride, p-toluenesulfonyl chloride, triphenylchloromethane, 2,4-dimethoxybenzaldehyde, 2,4-dimethoxybenzyl chloride, 4-methoxybenzaldehyde, 4-methoxybenzaldehyde Oxybenzyl chloride, benzyl chloride or benzyl bromide; (2)制备式III所示的N-保护基-4-异丁氧基苄胺:(2) N-protecting group-4-isobutoxybenzylamine shown in the preparation formula III: N-保护基-4-羟基苄胺与溴代异丁烷进行烃化反应制得;Prepared by alkylation reaction of N-protecting group-4-hydroxybenzylamine and bromoisobutane; (3)制备式IV所述的4-异丁氧基苄胺:(3) 4-isobutoxybenzylamine described in the preparation formula IV: N-保护基-4-异丁氧基苄胺,脱去氨基保护基制得;N-protecting group-4-isobutoxybenzylamine, obtained by removing the amino protecting group; (4)制备式V所述的N-(4-异丁氧基苄基)氨基甲酸苯酯:(4) N-(4-isobutoxybenzyl) phenyl carbamate described in the preparation formula V: N-保护基-4-异丁氧基苄胺,经过氨基脱保护基后、与氯甲酸苯酯反应制得;N-protecting group-4-isobutoxybenzylamine, prepared by reacting with phenyl chloroformate after deprotecting the amino group; (5)制备式VII所述N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐:(5) Tartrate of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea described in the preparation formula VII : N-(4-异丁氧基苄基)氨基甲酸苯酯,与另一中间体N-(4-氟苄基)-1-甲基-4-哌啶胺通过氨解反应,与酒石酸成盐制得;N-(4-isobutoxybenzyl) phenyl carbamate, with another intermediate N-(4-fluorobenzyl)-1-methyl-4-piperidinamine, reacts with tartaric acid by aminolysis salt made; 其中,步骤(1)和(2)中,X为苄氧羰基、笏甲氧羰基、叔丁氧羰基、三甲基硅乙氧羰基、甲氧羰基、乙氧羰基、甲酰基、乙酰基、对甲苯磺酰基、三苯甲基、2,4-二甲氧基苄基、4-甲氧基苄基或苄基。Wherein, in steps (1) and (2), X is benzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, trimethylsilylethoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, formyl, acetyl, p-toluenesulfonyl, trityl, 2,4-dimethoxybenzyl, 4-methoxybenzyl or benzyl. 3.N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,以4-羟基苄胺为原料,经过氨基保护处理得N-保护基-4-羟基苄胺、再与溴代异丁烷进行烃化反应制得N-保护基-4-异丁氧基苄胺,然后经氨基脱保护得4-异丁氧基苄胺、再与氯甲酸苯酯反应制得。3. The synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate is characterized in that, with 4-hydroxybenzylamine as raw material, N-protecting group-4-hydroxybenzylamine is obtained through amino protection treatment , and then carry out alkylation reaction with bromoisobutane to obtain N-protecting group-4-isobutoxybenzylamine, then deprotect the amino group to obtain 4-isobutoxybenzylamine, and then react with phenyl chloroformate be made of. 4.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,保护试剂为氯甲酸乙酯。4. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate according to claim 3, is characterized in that, protecting reagent is ethyl chloroformate. 5.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,所述的N-保护基-4-羟基苄胺通过如下方法制备:将4-羟基苄胺、保护试剂、缚酸剂,按照摩尔比1:(1.1-2.5):(1.2-3)加入到溶剂中,-25~60℃反应0.5-24h,获得N-保护基-1-(4-羟基苄基)胺;所述的溶剂为二氯甲烷、二氧六环、四氢呋喃、甲苯、乙腈、氯仿或各溶剂与水的混合溶剂,缚酸剂为碳酸氢钠、碳酸氢钾、三乙胺。5. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, described N-protecting group-4-hydroxybenzylamine Prepared by the following method: add 4-hydroxybenzylamine, protective reagent, and acid-binding agent into the solvent according to the molar ratio of 1:(1.1-2.5):(1.2-3), react at -25~60°C for 0.5-24h, Obtain N-protecting group-1-(4-hydroxybenzyl)amine; the solvent is dichloromethane, dioxane, tetrahydrofuran, toluene, acetonitrile, chloroform or a mixed solvent of each solvent and water, acid-binding agent For sodium bicarbonate, potassium bicarbonate, triethylamine. 6.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,所述的N-保护基-4-羟基苄胺通过如下方法制备:将4-羟基苄胺、保护试剂、缚酸剂:摩尔比为1:(1.1-1.2):1.5加入到溶剂中,0~25℃反应0.5-24h,获得N-保护基-1-(4-羟基苄基)胺;所述的溶剂为二氯甲烷;缚酸剂为碳酸氢钠。6. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, described N-protecting group-4-hydroxybenzylamine Prepared by the following method: add 4-hydroxybenzylamine, protective reagent, acid-binding agent: molar ratio 1:(1.1-1.2):1.5 into the solvent, react at 0-25°C for 0.5-24h, and obtain N-protecting group -1-(4-hydroxybenzyl)amine; the solvent is dichloromethane; the acid-binding agent is sodium bicarbonate. 7.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,N-保护基-4-异丁氧基苄胺通过如下方法制备:7. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, N-protecting group-4-isobutoxybenzylamine Prepared by: 将N-保护基-4-羟基苄胺、溴代异丁烷与缚酸剂按照摩尔比1:(1.2-3):(1.2-3),加入溶剂中,50~82℃下反应12-36h,反应结束后,溶剂用碱水洗,弃掉水层,脱去溶剂,制得N-保护基-4-异丁氧基苄胺;所述的溶剂为:DMF、DMA、乙醇、乙腈、四氢呋喃;缚酸剂为无水碳酸钠、无水碳酸钾、DBU。Add N-protecting group-4-hydroxybenzylamine, bromoisobutane and acid-binding agent into the solvent at a molar ratio of 1:(1.2-3):(1.2-3), and react at 50-82°C for 12- 36h, after the reaction, the solvent was washed with alkaline water, the water layer was discarded, and the solvent was removed to obtain N-protecting group-4-isobutoxybenzylamine; the solvents were: DMF, DMA, ethanol, acetonitrile, Tetrahydrofuran; acid binding agent is anhydrous sodium carbonate, anhydrous potassium carbonate, DBU. 8.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,将N-保护基-4-羟基苄胺、溴代异丁烷与缚酸剂按照摩尔比1:(1.2-1.5):(1.5-2),加入溶剂中,55~82℃下反应12-36h,反应结束后,溶剂用碱水洗,弃掉水层,脱去溶剂,制得N-保护基-4-异丁氧基苄胺;所述的溶剂为DMF;缚酸剂为无水碳酸钾。8. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, N-protecting group-4-hydroxybenzylamine, bromine Substituted isobutane and acid-binding agent are added into the solvent according to the molar ratio of 1:(1.2-1.5):(1.5-2), and reacted for 12-36 hours at 55-82°C. After the reaction, the solvent is washed with alkaline water and discarded. The aqueous layer was removed from the solvent to obtain N-protecting group-4-isobutoxybenzylamine; the solvent was DMF; the acid-binding agent was anhydrous potassium carbonate. 9.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,4-异丁氧基苄胺通过如下方法制备:9. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, 4-isobutoxybenzylamine is prepared by the following method: 将N-氨基保护基-1-(4-异丁氧基苄基)胺与脱保护试剂按照摩尔比1:(3-10),加入溶剂中,-25~80℃下反应3-8h,制得4-异丁氧基苄胺,所述的溶剂为甲醇、乙醇、异丙醇、DMF、二氯甲烷;脱保护试剂为氢氧化钠、氢氧化钾、甲醇钠、乙醇钠、水合肼,三氟乙酸、盐酸。Add N-amino-protecting group-1-(4-isobutoxybenzyl)amine and deprotection reagent into the solvent at a molar ratio of 1:(3-10), and react at -25~80°C for 3-8h, Obtain 4-isobutoxybenzylamine, described solvent is methanol, ethanol, isopropanol, DMF, methylene chloride; Deprotection reagent is sodium hydroxide, potassium hydroxide, sodium methylate, sodium ethylate, hydrazine hydrate , trifluoroacetic acid, hydrochloric acid. 10.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,N-氨基保护基-1-(4-异丁氧基苄基)胺与脱保护试剂按照摩尔比1:(3-4),加入溶剂中,50~80℃下反应3-8h,制得4-异丁氧基苄胺,所述的溶剂为乙醇;所述脱保护试剂为氢氧化钾或三氟乙酸。10. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate according to claim 3, is characterized in that, N-amino protecting group-1-(4-isobutyl Oxybenzyl) amine and deprotection reagent according to molar ratio 1: (3-4), add in solvent, react 3-8h at 50~80 ℃, obtain 4-isobutoxybenzylamine, described solvent is ethanol; the deprotection reagent is potassium hydroxide or trifluoroacetic acid. 11.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,N-(4-异丁氧基苄基)氨基甲酸苯酯通过如下方法制备:11. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, N-(4-isobutoxybenzyl) amino Phenyl formate is prepared by the following method: 将4-异丁氧基苄胺、氯甲酸苯酯与缚酸剂按照摩尔比1:(1.1-2):(1.2-3)加入溶剂中,-25~60℃下反应0.5-3h,反应结束后,脱去溶剂,残留物水洗,固体抽滤,制得N-(4-异丁氧基苄基)氨基甲酸苯酯,所述的溶剂为二氯甲烷、二氧六环、四氢呋喃、甲苯、甲醇、乙醇、异丙醇、乙腈;缚酸剂为三乙胺、碳酸氢钠、碳酸氢钾、无水碳酸钠、无水碳酸钾、氢氧化钠、氢氧化钾。Add 4-isobutoxybenzylamine, phenyl chloroformate and acid-binding agent into the solvent according to the molar ratio of 1:(1.1-2):(1.2-3), react at -25~60°C for 0.5-3h, and react After the end, the solvent is removed, the residue is washed with water, and the solid is suction filtered to obtain N-(4-isobutoxybenzyl)phenyl carbamate. The solvent is dichloromethane, dioxane, tetrahydrofuran, Toluene, methanol, ethanol, isopropanol, acetonitrile; acid binding agent is triethylamine, sodium bicarbonate, potassium bicarbonate, anhydrous sodium carbonate, anhydrous potassium carbonate, sodium hydroxide, potassium hydroxide. 12.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法或权利要求3所述的N-(4-异丁氧基苄基)氨基甲酸苯酯的合成方法,其特征在于,将4-异丁氧基苄胺、氯甲酸苯酯与缚酸剂按照摩尔比1:(1.1-2):(1.2-3)加入溶剂中,-25~60℃下反应0.5-3h,反应结束后,脱去溶剂,残留物水洗,固体抽滤,制得N-(4-异丁氧基苄基)氨基甲酸苯酯,所述溶剂为二氯甲烷,缚酸剂为无水碳酸钾。12. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate or the synthetic method of N-(4-isobutoxybenzyl) phenyl carbamate described in claim 3, is characterized in that, 4-isobutoxybenzylamine, chloroformic acid benzene The ester and the acid-binding agent are added into the solvent according to the molar ratio of 1:(1.1-2):(1.2-3), and react at -25~60°C for 0.5-3h. After the reaction is completed, the solvent is removed, the residue is washed with water, and the solid is extracted Filter to obtain N-(4-isobutoxybenzyl) phenyl carbamate, the solvent is dichloromethane, and the acid-binding agent is anhydrous potassium carbonate. 13.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法,其特征在于,N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐通过如下方法制备:13. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate is characterized in that, N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea The tartrate salt is prepared by the following method: 将N-(4-氟苄基)-1-甲基-4-哌啶胺、N-(4-异丁氧基苄基)氨基甲酸苯酯与酒石酸按照摩尔比1:(1.1-1.5):(0.5-1),将上述哌啶胺与氨基甲酸苯酯加入溶剂中,25~100℃反应3-12h,反应结束后,温度降至40℃,该温度下加入酒石酸固体搅拌2小时,反应停止并降至室温析晶,抽滤,制得所述N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐;N-(4-fluorobenzyl)-1-methyl-4-piperidinamine, N-(4-isobutoxybenzyl)phenyl carbamate and tartaric acid in a molar ratio of 1:(1.1-1.5) : (0.5-1), adding the above-mentioned piperidinamine and phenyl carbamate into the solvent, reacting at 25-100°C for 3-12h, after the reaction, the temperature dropped to 40°C, adding tartaric acid solid at this temperature and stirring for 2 hours, The reaction was stopped and dropped to room temperature for crystallization, suction filtration, and the N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxy benzyl) urea tartrate; 所述溶剂为无水甲醇、无水乙醇、异丙醇、甲苯或乙腈。The solvent is absolute methanol, absolute ethanol, isopropanol, toluene or acetonitrile. 14.如权利要求1或2所述的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐的合成方法,其特征在于,N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐通过如下方法制备:14. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea as claimed in claim 1 or 2 The synthetic method of tartrate is characterized in that, N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-isobutoxybenzyl)urea The tartrate salt is prepared by the following method: 将N-(4-氟苄基)-1-甲基-4-哌啶胺、N-(4-异丁氧基苄基)氨基甲酸苯酯与酒石酸按照摩尔比1:(1.2-1.3):(0.5-0.52),将上述哌啶胺与氨基甲酸苯酯加入溶剂中,温度为65~78℃反应3-12h,反应结束后,温度降至40℃,该温度下加入酒石酸固体搅拌2小时,反应停止并降至室温析晶,抽滤,制得所述N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-异丁氧基苄基)脲的酒石酸盐;所述溶剂为无水乙醇。N-(4-fluorobenzyl)-1-methyl-4-piperidinamine, N-(4-isobutoxybenzyl)phenyl carbamate and tartaric acid in a molar ratio of 1:(1.2-1.3) : (0.5-0.52), the above-mentioned piperidine amine and phenyl carbamate are added in the solvent, and the temperature is 65~78° C. for 3-12 hours. Hours, the reaction was stopped and dropped to room temperature for crystallization, suction filtration to obtain the N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-iso butoxybenzyl) urea tartrate; the solvent is absolute ethanol.
CN201510259570.7A 2015-05-20 2015-05-20 A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea Active CN104961672B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510259570.7A CN104961672B (en) 2015-05-20 2015-05-20 A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510259570.7A CN104961672B (en) 2015-05-20 2015-05-20 A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea

Publications (2)

Publication Number Publication Date
CN104961672A CN104961672A (en) 2015-10-07
CN104961672B true CN104961672B (en) 2017-10-20

Family

ID=54215798

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510259570.7A Active CN104961672B (en) 2015-05-20 2015-05-20 A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N ' (4 isobutoxy benzyl) urea

Country Status (1)

Country Link
CN (1) CN104961672B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325444B1 (en) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
CN105153016B (en) * 2015-10-12 2017-10-03 北京诺康达医药科技有限公司 A kind of Mo Fanselin preparation method
CN105523993A (en) * 2015-12-28 2016-04-27 重庆两江药物研发中心有限公司 N-(4-fluorobenzyl)-N-(1-methylpiperidinyl-4-yl)-N'-4-(2-methylpropoxyl)phenylmethyl)urea tartrate crystal form C, and preparation method and application thereof
CN107021917B (en) * 2016-02-02 2020-08-04 江苏恩华药业股份有限公司 Novel crystal form of pimavanserin hemitartrate and preparation method thereof
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
CN107286078A (en) * 2016-04-13 2017-10-24 广东东阳光药业有限公司 A kind of method for preparing pimaserin and tartrate thereof
WO2018049836A1 (en) * 2016-05-19 2018-03-22 上海诚妙医药科技有限公司 New crystalline form of pimavanserin tartrate, preparation method therefor, and use
CN106008323B (en) * 2016-05-30 2018-11-23 成都百裕制药股份有限公司 A method of preparing half tartrate crystal form C of piperazine Ma Selin
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
CN106946764A (en) * 2017-05-11 2017-07-14 成都百裕制药股份有限公司 A kind of method for preparing the tartrate crystal formation B of piperazine Ma Selin half
CN107200707B (en) * 2017-05-16 2020-10-02 河北科技大学 Preparation method of pimavanserin
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN108250087B (en) * 2018-03-15 2020-06-30 常州大学 A kind of synthetic method of 4-isobutoxybenzylamine
CN110894186B (en) * 2018-09-12 2022-05-24 浙江京新药业股份有限公司 Preparation method of pimavanserin and intermediate thereof
WO2020080217A1 (en) * 2018-10-19 2020-04-23 富士フイルム株式会社 Resin composition, cured film, laminate body, cured film production method, and semiconductor device
CN110156664B (en) * 2019-05-29 2022-03-01 常州大学 Method for synthesizing pimavanserin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780630A (en) * 1996-08-30 1998-07-14 Fmc Corporation Intermediate useful in the synthesis of pesticidal uracils
AR042649A1 (en) * 2002-12-23 2005-06-29 Syngenta Participations Ag ALCOHOL DERIVATIVES 2,6-DIHALO-4- (2,3-DICLORO-ALILOXI) -BENCILICO THAT HAVE INSECTICIDES AND ACARICIDES PROPERTIES
JP4996467B2 (en) * 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Synthesis of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N '-(4- (2-methylpropyloxy) phenylmethyl) carbamide and its tartrate salt and crystalline form
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
TW200804347A (en) * 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents

Also Published As

Publication number Publication date
CN104961672A (en) 2015-10-07

Similar Documents

Publication Publication Date Title
CN104961672B (en) A kind of synthetic method of the tartrate of N (4 luorobenzyl) N (base of 1 methyl piperidine 4) N &#39; (4 isobutoxy benzyl) urea
US11845729B2 (en) Processes and intermediates in the preparation of C5aR antagonists
JP4173003B2 (en) Urea derivatives as integrin α4 antagonists
AU2007243131A1 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
CN103288814B (en) A kind of preparation method of Rivaroxaban intermediate
TW202227397A (en) Bicyclic-heterocycle derivatives and related uses
CN102295594A (en) 4-N-substituted-1-(3-methoxylpropyl)-4-piperylhydrazine compound, preparation method thereof, and application thereof
WO2024108670A1 (en) Edoxaban key intermediate and synthesis method therefor
US9505719B2 (en) Synthesis and use of kinase inhibitors
CN107216271B (en) Tartaric acid Mo Fanselin impurity and preparation method thereof
CN111943945B (en) Suvorexant intermediate and preparation method thereof
EP3265460A1 (en) Tetrahydropyranyl benzamide derivatives
CN108409613A (en) Benzyl sulfamide derivative as RORc conditioning agents
CN114163408B (en) Benzo oxygen-containing heterocyclic compound and medical application thereof
CN114163426B (en) Benzo oxygen-containing heterocyclic compounds and their pharmaceutical applications
CN111825699B (en) Sulfur-containing heterocyclic compounds and process for producing the same
WO2024120275A1 (en) Preparation method for edoxaban and intermediate thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160714

Address after: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No.

Applicant after: Shenyang Pharmaceutical University

Applicant after: Hainan Shenzhou Kang Sheng Pharmaceutical Technology Co., Ltd.

Address before: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No.

Applicant before: Shenyang Pharmaceutical University

GR01 Patent grant
GR01 Patent grant